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Osteoarthritis is the most common arthritic condition, which involves progressive degeneration of articular cartilage. The most
recent accomplishments have signiﬁcantly advanced our understanding on the mechanisms of the disease development and
progression.Themostintriguing isthegrowingevidenceindicatingthatextracellular matrixdestruction inosteoarthriticarticular
cartilage resembles that in the hypertrophic zone of fetal growth plate during endochondral ossiﬁcation. This suggests common
regulatory mechanisms of matrix degradation in OA and in the development and can provide new approaches for the treatment
of the disease by targeting reparation of chondrocyte phenotype.
1.Introduction
Osteoarthritis (OA)is themost commonjoint disease, which
is associated with a risk of mobility disability. It aﬀects
approximately 12% of the aging Western population, while a
quarter of people aged over 55 have an episode of persistent
knee pain [1]. The pathology of OA involves the whole
joint and is associated with focal and progressive hyaline
articular cartilage loss, concomitant sclerotic changes in the
subchondral bone, and the developmentof osteophytes. Soft
tissuestructuresinandaroundthejoint includingsynovium,
ligaments, and muscles are also involved [2].
OA aﬀects predominantly articular cartilage, which
degrades by gradual loss of its extracellular matrix (ECM)
composed mainly of aggrecan and type II collagen. Loss of
large proteoglycan aggrecan decreases cartilage compressive
stiﬀness and precedes the damage to collagen ﬁbrillar
network, which is responsible for tensile properties of the
tissue [3]. Aggrecan degradation is associated with upreg-
ulation of aggrecanases a disintegrin and metalloprotease
with thrombospondin motifs (ADAMTS-) 4 and 5 as well
as matrix metalloproteinases (MMPs) [4]. The excessive
cleavage of type II collagen in OA is assumed to be
caused by the upregulation of the synthesis and activities of
collagenases [5–7], in particular MMP-13 [8–10]. Presently,
it is believed that articular cartilage destructionin OA results
from excessive loading, age-related changes, and metabolic
i m b a l a n c ei nt h et i s s u e[ 11–13].
OA also exhibits features of a systemic disease as it has
been shown to involve vascular pathology [14, 15]a sw e l l
as T-cell immune response [16, 17] associated with upreg-
ulation of cytokines such as interleukin (IL-) β and tumor
necrosis factor (TNF)α [3, 18], which aggravate cartilage
resorption [19].Asthemechanism ofOA developmentis not
completely understood, the disease manifestations, which
are associated with cartilage resorption and inﬂammation,
suggest a treatment involving inhibition of proinﬂammatory
cytokines or MMP activity to prevent matrix destruction.
However, it does not result in disease modiﬁcation and
produces severe side eﬀects [20, 21].
Articular cartilage degeneration in OA is also associated
with changes in chondrocyte phenotype [13, 22, 23]. Specif-
ically, these changes resemble those observed during chon-
drocyte diﬀerentiation in endochondral ossiﬁcation and are
characterized by cell cloning, expression of diﬀerentiation-
related genes such as parathyroid hormone-related peptide
(PTHrP) [24], type X collagen [25–27], annexins and
alkaline phosphatase (ALP)[28,29],osteocalcin[30],matrix
calciﬁcation [31, 32], as well as apoptotic cell death of
terminally diﬀerentiated chondrocytes [33, 34]. All these2 Arthritis
cellular changes including increased cleavage of type II
collagen by MMP-13 are also associated with chondrocyte
hypertrophy observed in the growth plate [35]. This suggests
that, as articular cartilage shares a common embryological
origin with the epiphyseal growth plate [36], destruction
of cartilage matrix in OA may involve some of the same
cellular and regulatory mechanisms that govern normal
chondrocyte terminal diﬀerentiation and ECM resorption in
skeletal growth and repair [22].
The aim of this paper is to summarize current evi-
dence supporting the involvement of molecular mechanisms
observed in the course of chondrocyte progression through
the growth plate in cartilage matrix destruction in OA.
2.Zonal Gene ExpressioninEpiphyseal
GrowthPlate
A central process in endochondral bone formation is a
progressivediﬀerentiationofproliferatingmatrix assembling
chondrocytes to growth-arrested hypertrophic cells. This
involves remodeling and mineralization of the cartilage
matrix and leads eventually to its subsequent replacement by
bone.
Primary mammalian growth plate physis is structurally
organized and can be divided into zones, namely, the resting,
proliferative, and hypertrophic. Resting zone chondrocytes
showverylimited celldivision evidencedbylowproliferating
cell nuclear antigen (PCNA) expression [37]. They elaborate
an extensive extracellular matrix, which is composed pre-
dominantly of type II collagen and proteoglycan aggrecan;
however, it also contains other collagen types VI, IX, XI,
link protein, and small leucine-rich proteoglycans (SLRPs)
such as decorin and ﬁbromodulin [37]. Expression of several
regulatory growth factors, such as bone morphogenetic pro-
teins (BMPs-) 3, 5, 7, ﬁbroblast growth factor (FGF-) 2, and
transforming growth factor (TGF)β1–3 has been detected in
this zone as well [37–43].
In contrast to resting zone, proliferative zone chondro-
cytes actively divide, which is evidenced by the expression of
cyclins [35, 44] and the presence of PCNA positive cells [45].
They produce long columns of ﬂattened cells and express
hyaline ECM similar to resting zone chondrocytes. The space
for the cells newly formed in the course of cell division is
generated by the matrix-degrading activity of collagenases
MMP-13, MT1-MMP [46, 47], and other MMPs such as
MMP-3 [48]. These cells also express proliferation-speciﬁc
growth factors, namely, TGFβ1–3, FGF-2 [35, 43, 49, 50],
PTHrP, insulin growth factor (IGF-) I and II [35, 51–53],
a cell death inhibitor that regulates apoptosis Bcl-2 (B-cell
lymphoma-2) [54], and transcription factor Sox9 (SRY-type
high-mobility-group box transcription factor 9) [35, 55].
AlthoughPTHrP [56], TGFβ2,and FGF-2 [57,58]havebeen
reported to stimulate MMP-13 expression in rodents, in the
early proliferative zone of the growth plate, their expression
does not induce signiﬁcant matrix loss probably due to the
lack of gelatinase (MMP-2 and -9) expression [35, 59].
Cessation ofcell division in the growth plate isassociated
with upregulation of cell cycle inhibitors p18, p19, and p21
[60], growth arrest and DNA damage-inducible (GADD)
45beta gene [61, 62], as well as apoptosis inhibitors Bcl2 and
Bag1 (Bcl2-associated athanogene 1), a Bcl2-binding protein
capable of enhancing Bcl2 activity [42, 63], and a marker of
apoptosiscaspase3[42].Atthispoint,chondrocytespartially
resorb their extracellular matrix, enlarge, round up, and
ﬁnally mature into hypertrophic cells, which express type X
collagen (COL10A1), a marker of chondrocyte hypertrophy.
Alkalinephosphataseshowsthemostpronouncedexpression
also in hypertrophic chondrocytes [64, 65]. This phenotypic
modiﬁcation in growth plate chondrocytes is associated with
dramatic alteration in regulatory gene expression, namely,
upregulation of growth factors such as TGFβ1a n d- 3[ 35,
50], BMP-2, -4, -6, and -7 [39, 40, 66–68], connective tissue
growth factor (CTGF) [69], vascular endothelial growth
factor (VEGF) [59, 70], and Indian hedgehog (Ihh) [35,
71, 72]. Inﬂammation-related cytokine IL-1 expression also
has been observed only in the hypertrophic chondrocytes
[73].
These regulatory growth factors are expressed in asso-
ciation with runt-related transcription factor (RUNX)2,
which is essential both for osteoblast diﬀerentiation [74]a n d
chondrocyte maturation during endochondral ossiﬁcation
[75–78], and is capable of inducing MMP-13 expression
[79, 80].
Expression of these growth and transcription factors is
also associated with upregulation of matrix proteins, such
as collagen type II (COL2A1) concomitantly with their
degrading enzymes MMP-13 and gelatinases MMP-2 and -
9[ 35, 67]. At this time, overt type II collagen degradation
occurs [46] indicating that genes for both matrix synthesis
and degradation are coregulated. However aggrecan remains
retained in the tissue at that time [3].
In the lower hypertrophic zone, mineralization (or
calciﬁcation) of residual matrix remaining after its resorp-
tion is initiated focally [3]. This involves deposition of
hydroxyapatite mineral [81]. Mineralization process in the
lower hypertrophic zone of the growth plate is associated
with expression of osteocalcin, which is a marker of mature
osteoblasts and is involved in chondrocyte mineralization
and Ca+2 homeostasis [28]. Upregulation of ankylosis pro-
tein (Ank), which is responsible for transport of intracellular
inorganic pyrophosphate to the extracellular milieu, has
been also observed in this zone [82]. Mineralization is
likely regulated by annexins II, V, and VI, which are highly
expressed in the hypertrophic and terminally diﬀerentiated
mineralizing growth plate chondrocytes and form calcium
channels enabling formation of ﬁrst mineral phase [83, 84].
For example, annexin V has been shown to be capable of
upregulating annexins II, VI, osteocalcin, Runx2, and ALP
as well as stimulating apoptotic activity in the lowest part of
the growth plate [83, 85]. In contrast, TGFβ2, which is also
expressed by lower hypertrophic chondrocytes [35], is most
probably involved in osteoblast formation [86].
Therefore, chondrocytematurationinthe growthplateis
associated with expression of stage-speciﬁc set of regulatory
growth and transcription factors producing changes in
cellular phenotype and synthesis of stage-speciﬁc extracel-
lular matrix, which eventually degrades in the hypertrophicArthritis 3
zone. All these cellular activities require careful and speciﬁc
coordination.
3.RegulationofGrowthPlateChondrocyte
Differentiation
Chondrocyte diﬀerentiation is initiated in the center of the
cartilaginous bone rudiment and is thought to be induced
by hypoxia and/or nutrient deﬁciency [87] .T h ep a c eo f
chondrocyte diﬀerentiation is regulated by various agents
including paracrine and autocrine growth factors and hor-
mones [3, 88]. They are responsible for speciﬁc regulatory
molecule expression by chondrocytes in the course of their
progression through the growth plate.
Growth factors secreted by fetal chondrocytes are in
charge of mutually exclusive processes of chondrocyte pro-
liferation and terminal diﬀerentiation. Thus, proliferation-
related growth factors such as basic ﬁbroblast growth factor
and parathyroid hormone-related peptide stimulate resting
chondrocytes to proliferate and suppress terminal diﬀeren-
tiation of hypertrophic chondrocytes [89–96]. In addition,
PTHrP, in combination with Indian hedgehog, regulates
chondrocyte diﬀerentiation through the establishment of
a negative feedback mechanism, whereby Ihh and PTHrP
can together suppress hypertrophy [97–100]. Alternatively,
interactions ofIhh with syndecan 3, which serves as a growth
factor coreceptor, are important for restricting mitotic
activity to the proliferative zone of mammalian growth plate
[101].
Transforming growth factor betas are multifunctional
molecules regulating cellular proliferation, diﬀerentiation,
and extracellular matrix function [75, 102]. TGFβ trans-
ported from apoptotic chondrocytes to the region of cell
division would be expected to stimulate matrix production,
delayhypertrophicdiﬀerentiation,andthusmaintain growth
plate width [103, 104]. TGFβ1[ 105–107]a n dT G F β2
[108] each are able to suppress chondrocyte hypertrophy
by coordinate inhibition of collagenase expression. This
is partially associated with upregulation of PTHrP gene
expression that exerts both PTHrP-dependent and PTHrP-
independent eﬀects on endochondral bone formation [105,
109, 110]. TGFβ2 in synergy with FGF-2 has been also
shown tosuppresschondrocytematurationandhypertrophy
[111, 112].
BMP signaling is also essential for chondrocyte progres-
sion through the growth plate [66]. Zone speciﬁc expression
of various BMPs suggests their involvement in chondrocyte
phenotypic changes in the course of both proliferation
and hypertrophy. Thus, BMP-2 and -6 have been shown
to promote chondrocyte hypertrophy by upregulation of
Ihh and type X collagen expression and downregulation
of FGF signaling involving Runx2 [113–118]. At the same
time, BMP-2 and -9 augmented mitogenic eﬀect of IGF-1,
while BMP-5 increased cell proliferationand cartilage matrix
synthesis [119, 120].
IGF-1, a structural and functional analog of insulin, pro-
motes chondrocyte proliferation and diﬀerentiation while
it inhibits apoptosis [89, 93]. It is also an important
regulator of PTHrP-Ihh feedback loop. The lack of IGF
resultsindownregulationofIhhexpressionandupregulation
of PTHrP [51]. IGF-1 favors chondrocyte hypertrophic
development as it induced type X collagen and alkaline
phosphatase in avian sternal chondrocytes [108, 112]. In
addition,insulinandIGF-1[121] bothare strong stimulators
of aggrecan and type II collagen synthesis [122].
Furthermore, chondrocyte diﬀerentiation in the growth
plate is regulated by various transcription factors [123].
Transcription factors Sox9 and -4 have been shown to
determine the rate of chondrocyte diﬀerentiation into
hypertrophy and the expression of chondrocyte-speciﬁc
matrix molecules including Col2A1, Col9A2, Col11A1, and
aggrecan [124–130]. They are also required to prevent
conversion of proliferating chondrocytes into hypertrophic
chondrocytes [55]. Transcription factors Runx1-3 are the
most important as they play a crucial role both in chon-
drocyte maturation and had been shown to induce MMP-
13 expression [77, 80, 125, 131]. Recently, the involvement
of several other transcription factors such as Shox/Shox2,
Dlx5, and MEF2C has been shown to control skeletal growth
thatsuggeststheirpotentialcontributioninectopicchondro-
cyte hypertrophy development[132, 133]. Wnt/beta-catenin
signaling can also mediate chondrocyte hypertrophy as it is
capable of upregulating type X collagen, Runx2, and alkaline
phosphatase expression while inhibiting Sox9 and type II
collagen expression [92].
Prostaglandin E2 (PGE2), a potent lipid molecule that
regulates a broad range of physiologic reactions, can inhibit
growth plate chondrocyte diﬀerentiation by downregulation
of diﬀerentiation-related genes COL10A1, VEGF, MMP-
13, and alkaline phosphatase expression as well as their
enzyme activity [134, 135]. At the same time, low con-
centrations of this prostaglandin are capable of increasing
proliferation of growth plate chondrocytes [136, 137]. In
contrast, chemokine stromal sell-derived factor 1, annexin
V, and Ank have been shown to stimulate hypertrophy,
mineralization, and apoptosis, when they are overexpressed
in nonmineralizing growth plate chondrocytes [82, 85, 138,
139].
Extracellular matrix proteins produced by chondrocytes
have also exhibited a capacity to regulate growth plate
chondrocyte hypertrophy. Thus, type II collagen, aggrecan,
and matrilin-3 are likely to inhibit hypertrophy as these
matrix component deﬁciency produced premature mat-
u r a t i o ni nm u t a n tc h o n d r o c y t e s[ 140–142]. Furthermore
a functional link between chondrocyte hypertrophy and
extracellular matrix degradationis also supported by the fact
that downregulation of chondrocyte hypertrophy evidenced
by suppression of type X collagen, Runx2 and MMP-13
expression is associated with inhibition of collagen cleavage
activity in cultured hypertrophic growth plate chondrocytes
treated with MMP-13 inhibitor [8, 143, 144]. This indicates
a functional link between chondrocyte hypertrophy and
extracellular matrix degradation.
It is necessary to note that variable eﬀects of regulatory
molecules are carefully coordinated to provide accuracy in
the process of endochondral ossiﬁcation. Thus, it has been
demonstrated that growth plate chondrocyte progression4 Arthritis
to hypertrophy is a subject to negative control that can
be arrested at various checkpoints [112]. Accordingly, an
early proliferative phenotype in avian fetal chondrocytes
has been reassumed by treatment with TGFβ2, FGF-2, and
insulin in combination, while diﬀerential Ihh expression was
responsible foracquisitionofthelateproliferativephenotype
in hypertrophic cells [112]. In another study, the release
of terminally diﬀerentiated hypertrophic chondrocytes from
their environment also resulted in downregulation of type X
collagen synthesis, activation of proliferation, and reinitia-
tion of aggrecan synthesis [145].
Therefore, chondrocyte diﬀerentiation is carefully regu-
lated in the course of endochondral ossiﬁcation. Eventually,
epiphysealchondrocytesgiverisetoarticularcartilage,whose
structural components and regulatory networks at least
partially resemble that in the growth plate.
4.Zonal Gene ExpressioninHealthy
ArticularCartilage
Healthy articular cartilage is characterized by a very low
expression of collagens type II, VI, IX, and XI [146]a n d
relatively high turnover rate for aggrecan [147]. It is also
characterized by expression of matrix turnover genes such
as MMP-3 [148], occasionally detected MMP-1, -8, -13
[149], and growth factors TGFβ1[ 150]a n dP T H r P[ 24,
151]. Antiangiogenic factor chondromodulin-1 [152, 153],
p16INK4α, and Gadd45α/β genes, the latter is associated
with environmental and intrinsic stress [154, 155], are
expressed in all the cartilage zones. At the same, time no
expression of type I and X collagens [156, 157], a complete
lack of expression of TGFβ2, IGF-1, Ihh [158, 159], annexin
VIII [160], and osteocalcin [30] was observed in healthy
cartilage.
Articular cartilage can be divided into superﬁcial, mid-,
anddeepzones;thelatterisfollowed bythecalciﬁedcartilage
providing junction of the cartilage to the subchondral bone
[157]. These zones diﬀer in expression of speciﬁc matrix
molecules, their modifying enzymes, and regulatory growth
factors, which are responsible for articular cartilage integrity
and function. Although normal articular chondrocytes are
less metabolically active than the growth plate chondrocytes,
some similarity in gene expression pattern in the individual
cartilage zones has been noted.
Superﬁcial zone of healthy articular cartilage contains
ﬂattened chondrocytes surrounded by specialized extracel-
lular matrix rich in thin collagen ﬁbrils [161]a n ds m a l l
leucine-rich proteoglycans-decorin and biglycan [162]. It
also contains the lowest amount of predominant cartilage
proteoglycan aggrecan compared to other zones of articular
cartilage. This zone is rich in regulatory molecules such
as TGFβ1a n d- 3a n dB M P1 – 6[ 37, 40]. Proliferative
potential of these cells is indicated by the expression of
cyclin D2; however, it may be suppressed by cell division
inhibitors such as growth arrest speciﬁc protein (Gas)-1 and
Gadd45α, which are also expressed in this cartilage zone
[37]. This is supported by the lack of superﬁcial chondrocyte
proliferative activity determined by PCNA staining [163].
MMP-3 expression was observed in this cartilage zone more
oftenthan MMP-1, -8, and-13,howevertheseproteinases do
not produce any matrix degradation and are likely involved
in matrix turnover [149, 164]. Expression of antiapoptotic
Bcl2and Bag1geneswasdetectedpredominantly inthiszone
in old mice, while it was observed throughout the articular
cartilage in the young animals [63].
Mid-zone chondrocytes are round in shape, surrounded
by ECM composed of thick collagen ﬁbrils and rich in
aggrecan. Chondrocytes in this zone do not show any
proliferative activity determined by PCNA staining similar
to superﬁcial zone cells [163]. However, these cells are likely
to possess a potential for proliferation, as FGF-2, capable
of inducing proliferation in normal articular chondrocytes
in culture [165], has been detected in the mid-zone of
mouse articular cartilage [49]. BMP1–7 expression was also
observed in the mid-zone of normal articular cartilage
[40].
Deep zone chondrocytes are grouped in clusters and
resemble hypertrophic chondrocytes of the growth plate [3].
In this zone, cartilage matrix has the highest content of
aggrecan [166], the lowest amounts of small leucine-rich
proteoglycans [162], and the largest diameter of collagen
ﬁbrils. Similar to hypertrophic zone of the growth plate,
BMP1–7 [40], Ihh expression [167], and the highest amount
of annexin VI-positive cells were observed in the deep
zone of human articular cartilage [163]. The lowest part
of the deep zone, which is partly calciﬁed, expressed a
marker of chondrocyte hypertrophy type X collagen and
is rich in alkaline phosphatase. MMP-13 expression [149]
and negligible activity of chondrocyte apoptosis was also
sometimes observed here [168, 169].
However, in spite of low activity of cellular and matrix
turnover, healthy articular cartilage possesses a strong
metabolic potential, whose activation is observed during
development of pathological condition such as OA.
5.EarlyDevelopmentofOsteoarthritis
Early OA changes in articular cartilage are associated with
signiﬁcant metabolic activation of articular chondrocytes.
This involves sequential and zonal upregulation of chondro-
cyte diﬀerentiation-related genes as well as an increase in
the activity of the same MMPs, which are responsible for
matrix degradation in the hypertrophic zone of the growth
plate. Spatially, these genes are upregulated in the mid- and
superﬁcial zones of articular cartilage, where lately the ﬁrst
signs of cartilage destruction occur.
Mild OA changes (Mankin 1–4) are characterized by the
loss of proteoglycans in the surface area [163, 170, 171].
Although these changes were not accompanied by signiﬁcant
structural disturbances in the tissue, they were associated
with increased type II collagen and aggrecan synthesis,
upregulation of chondrocyte proliferation evidenced by
increased PCNA and Ki67 staining and MMP-13 expression
[172–175]. This was followed by the cellular changes similar
to those observed in hypertrophic zone of the growth plate
as indicated by type X collagen production, collagenaseArthritis 5
and alkaline phosphatase staining, and increased type II
collagen cleavage activity in the mid-zone [172, 176]. Later,
chondrocyteactivationextendstothesuperﬁcial zone,where
it is accompanied by chondrocyte apoptosis evidenced by
t h ep r e s e n c eo ft h ec e l l sc a r r y i n gD N An i c k s[ 172]. IL-1β
expression is also upregulated both in the superﬁcial and
deep cartilage zones in early OA [177]. Similar to biphasic
MMP-13 expression in the growth plate, upregulation of this
collagenase in the articular cartilage was initially preceded
and later accompanied by type X collagen and alkaline
phosphatase expression [172, 176].
An early OA articular cartilage degeneration is observed
focally. Spatial distribution of chondrocyte diﬀerentiation-
related gene expression in the areas adjacent to and remote
from the early lesion also resembles that in the growth
plate and is associated with increased collagenase cleavage of
typeIIcollagen.Thus,collagenasesMMP-1, MMP-14 (MT1-
MMP), and aggrecanase ADAMTS-5 (but not ADAMTS-
4), cytokines IL-1α/β and TNF-α, chondrocyte terminal
diﬀerentiation-related genes COL10A1, MMP-13, MMP-9,
Ihh, and caspase 3 were often upregulated in the vicinity
of the lesion. Growth factors associated with growth plate
chondrocyte proliferation, namely, FGF-2, PTHrP, and TGF
β1/2, as well as the matrix molecules COL2A1 and aggrecan,
were expressed adjacent to and remote from the lesion
[22]. In addition, a distinct spatial reorganization in human
superﬁcial chondrocytes in remote area from early OA
lesions has been recently reported [178].
However, of all genes, only caspase 3 and ADAMTS-
5 expression was exclusively seen in association with early
lesions. Elevation of collagenase activity was associated with
afrequentelevationofexpressionofCOL10A1,caspase3,IL-
1α/β,MMP-1,andADAMTS-5andadecreasedexpressionof
Sox-9, TGF-β1, TGF-β2, TNF-α, and aggrecan [22].
Moderate OA changes in the articular cartilage (Mankin
6–9), which are characterized by the lack of ﬁbrillations,
some loss of superﬁcial zone, and some clustering of cells
[163, 171], are associated with the increase of PCNA staining
in the superﬁcial zone and annexin VI and VIII antigen
upregulation in the mid- and deep zones [160, 163, 179].
Therefore, articular chondrocyte activation in early OA,
which is the most pronounced in the superﬁcial and mid-
zones, resembles that observed during chondrocyte matura-
tion in the growth plate.
6.Gene Expressionin Late
OsteoarthriticCartilage
Severe OA (Mankin ≥10) is characterized by extensive
ﬁssuring andﬁbrillation,clusteringofchondrocytes,andloss
of cartilage [163]. Cartilage zonal organization is disturbed.
The superﬁcial zone degradation produces rough ﬁbrillated
surface, ﬁssures, and cracks extending to the calciﬁed zone.
This is accompanied by severe proteoglycan loss followed
by degradation of type II collagen [164, 180]. Collagen
degradation occurs around chondrocytes. At this time,
upregulation of MMPs-13, -2, -11, ADAMTS as well as
expression of collagens type I, II, III, VI, and X were
observed near the articular surface [148, 181–183]a n dw a s
accompanied by strong expression of IL-1β and TNFα [149].
At the same time, collagen replenishment is limited as Col2A
N-propeptide, a marker of collagen synthesis, was detected
only in the deep zone close to subchondral bone [184].
As it was stated above, all these gene activities have been
also observed in the hypertrophic zone of the fetal growth
plate.
Chondrocyte terminal diﬀerentiation-related gene
expression is also observed in cell clusters located around
ﬁssures [185, 186]. In these clusters, both collagen type II
and X synthesis [187]a sw e l la sT G F β3 and its receptor
regulator Smad-2P expression were observed [188].
PCNA and syndecan-3, the markers of early fetal
chondrocyte diﬀerentiation, as well as annexin VI and
alkaline phosphatase, which are involved in terminal stage
of diﬀerentiation, all are upregulated near articular surface
in human OA articular cartilage [30, 163]. At the same time,
annexin VIII and osteocalcin, which were never detected in
normal articular cartilage, were observed in the mid- and
deep zones in late OA cartilage [30, 160]. An increase in
BMP-2 expression [188] was associated with upregulation
of tumor suppressor p53 expression [189] and cyclin-
dependentkinase inhibitor p16INK4aupregulationin all the
cartilage zones [155] indicating inhibition of proliferative
potential in late OA chondrocytes. However, repression of
antiproliferativefactorTob1hasbeenalsoreportedinthelate
s t a g eo fk n e eO Ac a r t i l a g e[ 183].
The most severely damaged rodent knee OA articu-
lar cartilage has shown signiﬁcantly reduced expression
of proliferation-related growth factors and their signaling
molecules such as PTHrP, TGFβ3a n dS m a d - 2 P ,T G F β1
and its receptor II [188, 191]. However, in human hip OA,
both downregulation and upregulation of TGFβ1–3 isoform
expression compared to healthy cartilage have been reported
[43, 192], while one study failed to detect any upregulation
of chondrocyte diﬀerentiation and hypertrophy markers
associated with late OA [193].
Antiangiogenic factor chondromodulin-1 downregula-
tion concomitantto VEGF upregulationindicating increased
vascular invasion into cartilagein advanced OA has beenalso
observed [194, 195]. This was accompanied by upregulation
of chondrocyte apoptosis, a marker of the ﬁnal step of
chondrocyte diﬀerentiation, which was more pronounced in
OA cartilage compared to normal specimens [189].
Overall degrading activity prevailed over synthesis as
serum levels of Col2A N-propeptide were lower than that of
collagen degradation products in late OA patients compared
to controls indicating the uncoupling of collagen synthesis
and degradation in OA [190]. Moreover, serum increase
in both Col2A N-propeptide and collagen degradation
fragments was often indicativeonthe most aggressive disease
progression [196].
Thus, the similarity in the gene expression proﬁles asso-
ciated with matrix destruction in OA articular cartilage and
in the hypertrophic zone of the growth plate observed in the
majority of studies suggests an acquisition of hypertrophic
phenotype traits by OAarticular chondrocytes.6 Arthritis
7.InhibitionofArticularChondrocyte
HypertrophySuppressesOA Cartilage
Degeneration
The similarity of ECM degradation in OA to that in the
hypertrophic zone of primary growth plate involves upregu-
lation of type II collagen cleavage by collagenase and expres-
sion of regulatory diﬀerentiation-related growth factors and
matrix proteins, which are associated with chondrocyte
hypertrophy [6, 22, 25, 28]. Therefore, the aboveobservation
that hypertrophic changes in the growth plate chondrocytes
are reversible [112] suggests a possibility for OA articular
chondrocytes to regain healthier phenotype when they are
treated by the agents inhibiting fetal hypertrophy.
In fact, the same growth factors, namely, TGFβ2, FGF-
2, and insulin, which were previously used individually or in
combination to suppress hypertrophy in growth plate chon-
drocytes [112], have been shown to be capable of arresting
type II collagen cleavage,chondrocyte diﬀerentiation-related
gene, and proinﬂammatory cytokine expression in human
OA articular cartilage explants [197]. Another combination
ofTGFβ1 and IGF1 inhibited collagendegradation, a marker
of extracellular matrix destruction, which was induced
by oncostatin M and TNFα in bovine articular cartilage
[198]. It has been also shown that TGFβ inhibition of
chondrocyte diﬀerentiation is likely mediated by Smad2/3
pathway through modulation of Runx2 function [75]. In
another study, a major proliferation-related growth factor
PTHrP downregulated terminal diﬀerentiation-related genes
in cultured mineralizing articular chondrocytes from the
deep zone as well as in chondrogenic articular cartilage con-
structs[199,200].Itisworthtonoteherethatgrowthfactors,
which were capable of inhibiting collagen degradation in
OA articular cartilage, are predominantly expressed in the
proliferative zone of the growth plate and are required for
chondrocyte proliferation in the development.
Similareﬀectonsuppressionofcollagencleavageinasso-
ciation with inhibition of chondrocyte hypertrophy-related
genes and proinﬂammatory cytokines IL-1β and TNFα
has been observed on treatment of OA explants with low
concentrations of PGE2 [201]. Although PGE2 is expressed
in all the growth plate zones, it is primarily required for
fetal chondrocyte proliferation [137]a n di sc a p a b l ea l s o
of inhibiting their terminal diﬀerentiation [134, 135]a n d
expression of proinﬂammatory mediators [202]. At the same
time, PGE2 at higherconcentrations hasbeenshown toexert
stimulating eﬀects on cartilage degradation [203].
Alternatively, downregulation of the genes, which are
expressed in the hypertrophic zone of the growth plate and
associated with chondrocyte terminal diﬀerentiation such
as Hedgehog signaling, TGFβ1/BMP signaling, transform-
ing growth factor-beta-activated kinase (TAK) 1, cyclin-
dependent kinase inhibitor p16INK4a, ADAMTS5, RUNX2,
and caspases, resulted in abrogation of matrix degeneration,
less type X collagen production, and MMP-13 expression
[155, 204–210]. Therefore, upregulation of the genes asso-
ciated with growth plate chondrocyte proliferation or down-
regulation of hypertrophy-related genes favors acquisition of
healthier phenotype in OA articular chondrocytes.
However, while direct inhibition of cartilage degradation
by the agents capable of regulating chondrocyte diﬀerentia-
tion is an attractive means to counteract articular cartilage
degeneration in OA, it has several limitations. Thus, fol-
lowing the inhibition of cartilage degradation by individual
growth factors (GFs) reparation of articular cartilage in OA
in vivo may require a combination of GF [18, 211, 212]. For
example, being the most eﬃcientinsuppressing OA articular
cartilage destruction [197], TGFβ2a l o n em a yn o tb ec a p a b l e
of restoring the anabolic functions of healthy articular
cartilage since it has been reported to downregulate type
II collagen and aggrecan synthesis [108, 213]. In contrast,
in responsive individuals, insulin may facilitate tissue repair
as it is a principal anabolic agent in the articular cartilage
[214]. FGF-2 can also promote cartilage repair [212]b y
itself or inducing local TGFβ or its own expression [215].
In addition, combinations of these and other growth factors
havebeen shown toproducesynergistic eﬀectin maintaining
synthesis of matrix molecules in articular and growth plate
chondrocytes [108, 216, 217].
Another concern on GF application is related to their
possible catabolic eﬀects. Although no evidence has been
obtained that TGFβ2 can act catabolically in human OA
articular cartilage [197], destructive potential of this growth
factorathighconcentrationwasobservedinnormalarticular
cartilage in vivo after its intraarticular injections, which
produced joint swelling, ﬁbroblastic proliferation of synovial
membrane, and profound loss of articular cartilage pro-
t e o g l y c a ni nr a b b i tj o i n t s[ 213]. Therefore, the delivery of
exact therapeutic amount of the growth factor to the site of
articular cartilage destruction may be important. This has
beendemonstrated ina recent study, where deleteriouseﬀect
of TGFβ1 capable of inducing synovial ﬁbrosis has been
counteracted by combined overexpression of TGFβ1a n di t s
inhibitor Smad7 [188]. This resulted both in prevention of
proteoglycan (PG) loss and in increase in PG content in
mouse OA cartilage.
8.Modeling of OA-Related Changes in Healthy
ArticularCartilageIsAssociated with
Chondrocyte HypertrophyDevelopment
In healthy adult articular cartilage, chondrocyte diﬀeren-
tiation does not occur in the noncalciﬁed cartilage [218].
However, when maturational arrest is abolished, chondro-
cyte diﬀerentiation-related genes, which are barely expressed
in healthy articular cartilage, become upregulated followed
by hypertrophic changes in thecells and extracellular matrix.
If this notion is true, stimulation of degradation in healthy
articular cartilage should be accompanied by chondrocyte
hypertrophy development. The relieve of transcriptional
repression can be attained by cartilage treatment with
azacytidine C (Aza-C), which replaces cytidine bases in
genomic DNA during replication and disturbs methylation
pattern of cytidines (CpG islands) in target gene promoters.
This was associated with upregulation of PTHrP, governing
chondrocyte proliferation in the growth plate, as well as
chondrocyte hypertrophy-related collagen type X, Ihh, andArthritis 7
alkaline phosphatase gene expression, and the increase in
chondrocyte cell size in healthy articular cartilage [219–221].
On the other hand, alterations associated with chondro-
cyte hypertrophy in the growth plate are always accompa-
nied by overt extracellular matrix resorption producing its
degradation fragments [3]. Therefore, it is not surprising
that collagenand/orﬁbronectin degradationpeptides, which
can be also released on mechanical destruction of articular
cartilage caused by trauma or joint overload in case of
anterior cruciate ligament transection, have been shown to
be capable of inducing articular cartilage degradation by
upregulation of collagenase and MMPs activity [222–224].
Besides, these peptides upregulated chondrocyte prolifer-
ation, production of type X collagen and apoptotic cells
on the surface of articular cartilage explants [172, 224].
Collagen fragments may also account for OA-like changes
induced in healthy cartilage by overexpression of MMP-
13, which were associated with chondrocyte hypertrophy
in mouse articular cartilage [47]. In addition, other matrix
disturbances such as lack of matrilin-3 by a corresponding
geneknockoutproducedprematurechondrocytematuration
to hypertrophy and formed predisposition to develop severe
OA in mice [141].
Functional disturbances in the regulatory genes involved
in chondrocyte diﬀerentiation can also produce OA-related
changes in healthy articular cartilage resembling chondro-
cyte maturation in the growth plate. Thus, deﬁciency in
TGFβ signaling, which is essential for articular cartilage
maintenance and had been induced either by overexpression
of functionless TGFβ type II receptor [225] or by deletion of
Smad3 signaling [104, 226], caused accelerated chondrocyte
diﬀerentiation associated with type X collagen expression
and OA-like changes in articular cartilage. It has been also
shown that the absence of signaling through Fgfr (ﬁbroblast
growth factor receptor) 3 in the joints of Fgfr3(−/−)
mice produced premature cartilage degeneration and early
arthritis [227]. In contrast, TGFalpha signaling suggests
catabolic potential of this growth factor as it has been shown
to stimulate articular chondrocyte proliferation, formation
of cell clusters followed by expression of matrix-degrading
enzymes MMP-13, cathepsin C and downregulation of Sox9,
as well as collagen and aggrecan expression in rat articular
osteochondral explants [228].
Being an important factor of OA articular cartilage
pathology proinﬂammatory cytokines such as TNFα and IL-
1β have been shown to mediate articular cartilage degrada-
tionbyupregulationofmatrix-degradingMMPs[229].Ithas
been observed recently that increased expression of proin-
ﬂammatory agents such as TNFα,c h e m o k i n e sI L - 8 ,g r o w t h -
related oncogene α (GROα), or the multiligand receptor
for advanced glycation end products (RAGE) induced also
chondrocyte hypertrophy evidenced by collagen type X
expression [230, 231]. This suggests a link between inﬂam-
mation and altered diﬀerentiation in articular chondrocytes
[231]. Interestingly, the impairment TGFβ signaling by IL-
1β was mediated by downregulation of TGFβRII [232]. The
loss of function of this receptorhas previously been linked to
chondrocyte hypertrophy induction and OA developmentin
animal studies [225].
Therefore, OA-like alterations in healthy articular car-
tilage induced by the mediators, which are upregulated in
the hypertrophic zone during endochondral ossiﬁcation,
are accompanied by ECM degradation and associated with
articular chondrocyte hypertrophy.
9.Conclusions
The data presented here shows a signiﬁcant progress in
our understanding of molecular mechanisms of articular
cartilage degradation in OA. They involve at least in part
similar machinery of extracellular matrix resorption in
the hypertrophic zone of the growth plate and in OA
articular cartilage in the course of its degeneration. The
observation that profound cellular phenotypic changes in
articular chondrocytes occur prior the overt cartilage matrix
degradation monitored histologically suggests that articular
chondrocyte phenotype modiﬁcations can be recognized
very early in the disease at gene expression level favoring
timely disease recognition, which could help its prevention.
This implies also innovative opportunities in suppression of
cartilage matrix degradation targeting inhibition of chon-
drocytehypertrophy andsuggestsnewtargetsfortherapeutic
intervention. For this purpose, further studies are required
in search of new agents generating programmable articular
chondrocyte phenotype modiﬁcation.
Abbreviations
OA: Osteoarthritis
ECM: Extracellular matrix
MMP: Metalloproteinases
IL: Interleukin
ADAMTS: A disintegrin and metalloprotease with
thrombospondin motifs
PTHrP: Parathyroid hormone-related peptide
TNF: Tumor necrosis factor
ALP: Alkaline phosphatase
PCNA: Proliferating cell nuclear antigen
SLRPs: Small leucine-rich proteoglycans
BMP: Bone morphogenetic protein
FGF: Fibroblast growth factor
TGF: Transforming growth factor
TGFR: Transforming growth factor receptor
IGF: Insulin growth factor
Bcl-2: B-cell lymphoma 2
Sox9: SRY-type high-mobility-group box
transcription factor-9
GADD45beta: Growth arrest and DNA damage-inducible
45beta
Bag1: Bcl2-associated athanogene 1, a
Bcl2-binding protein capable of enhancing
Bcl2 activity
COL10A1: Type X collagen
BMP: Bone morphogenetic proteins
CTGF: Connective tissue growth factor
VEGF: Vascular endothelial growth factor
Ihh: Indian hedgehog
RUNX2: Runt-related transcription factor8 Arthritis
COL2A1: Collagen type II
Ank: Ankylosis protein
PGE2: Prostaglandin E2
Gas1: Growth arrest speciﬁc protein1
Aza-C: Azacytidine C
Fgfr3: Fibroblast growth factor receptor 3
RAGE: Multiligand receptor for advanced glycation
end products
GRO: Growth-related oncogene
PG: Proteoglycan
TAK: Transforming growth factor-beta-activated
kinase
GF: Growth factor.
Acknowledgment
The authoris supported by the Russian Foundationfor Basic
Research (Project no. 09-04-01158a).
References
[ 1 ]D .J .H u n t e ra n dD .T .F e l s o n ,“ O s t e o a r t h r i t i s , ”British
Medical Journal, vol. 332, no. 7542, pp. 639–642, 2006.
[ 2 ]S .B .A b r a m s o na n dM .A t t u r ,“ D e v e l o p m e n t si nt h e
scientiﬁc understanding of osteoarthritis,” Arthritis Research
&T h e r a p y , vol. 11, no. 3, article 227, 2009.
[3] A. R. Poole, “Cartilage in health and disease,” in Arthritis
and Allied Conditions: A Textbook of Rheumatology,W .
Koopman,Ed., pp. 223–269,Lippincott, Williams& Wilkins,
Philadelphia, Pa, USA, 15th edition, 2005.
[4] H. Nagase and M. Kashiwagi, “Aggrecanases and cartilage
matrix degradation,” Arthritis Research & Therapy,v o l .5 ,n o .
2, pp. 94–103, 2003.
[5] A. R. Poole, F. Nelson, L. Dahlberg et al., “Proteolysis
of the collagen ﬁbril in osteoarthritis,” Biochemical Society
Symposium, no. 70, pp. 115–123, 2003.
[6] A.R.Poole,F.Guilak,andS.B.Abramson,“Etiopathogenesis
of osteoarthritis,” in Osteoarthritis: Diagnosis and Medi-
cal/Surgical Management,R.W .M oskowitz,R.D .Altman,M.
C .H o c h b e r g ,J .A .B u c k w a l t e r ,a n dV .M .G o l d b e r g ,E d s . ,p p .
27–49, Williams & Wilkins,Lippincott, Pa, USA, 4th edition,
2007.
[ 7 ]A .R .P o o l e ,M .K o b a y a s h i ,T .Y a s u d ae ta l . ,“ T y p eI I
collagen degradation and its regulation in articular cartilage
in osteoarthritis,” Annals of the Rheumatic Diseases,v o l .6 1 ,
no. 2, pp. ii78–ii81, 2002.
[ 8 ]C .W .W u ,E .V .T c h e t i n a ,F .M w a l ee ta l . ,“ P r o t e o l y s i s
involving matrix metalloproteinase 13 (collagenase-3) is
required for chondrocyte diﬀerentiation that is associated
with matrix mineralization,” Journal of Bone and Mineral
Research, vol. 17, no. 4, pp. 639–651, 2002.
[9] R. C. Billinghurst, L. Dahlberg, M. Ionescu et al., “Enhanced
cleavage of type II collagen by collagenases in osteoarthritic
articular cartilage,” Journal of Clinical Investigation, vol. 99,
no. 7, pp. 1534–1545, 1997.
[10] L. Dahlberg, R. C. Billinghurst, G. Webb et al., “Selective
enhancement of collagenase-mediated cleavage of resident
type II collagen in cultured osteoarthritic cartilage and arrest
with a synthetic inhibitor that spares collagenase 1 (matrix
metalloproteinase 1),” Arthritis and Rheumatism, vol. 43, no.
3, pp. 673–682, 2000.
[11] T. Aigner, J.Haag,J. Martin,and J.Buckwalter,“Osteoarthri-
tis: aging of matrix and cells—going for a remedy,” Current
Drug Targets, vol. 8, no. 2, pp. 325–331, 2007.
[12] T. Aigner and N. Gerwin, “Growth plate cartilage as devel-
opmental model in osteoarthritis research potentials and
limitations,” Current Drug Targets, vol. 8, no. 2, pp. 377–385,
2007.
[13] P. M. van der Kraan, E. N. Blaney Davidson, and W. B.
van den Berg, “A role for age-related changes in TGF-
beta signaling in aberrant chondrocyte diﬀerentiation and
osteoarthritis,” Arthritis Research & Therapy, vol. 12, no. 1,
pp. 201–214, 2010.
[14] D. M. Findlay, “Vascular pathology and osteoarthritis,”
Rheumatology, vol. 46, no. 12, pp. 1763–1768, 2007.
[15] P. Ghosh and P. A. Cheras, “Vascular mechanisms in
osteoarthritis,” Best Practice and Research: Clinical Rheuma-
tology, vol. 15, no. 5, pp. 693–709, 2001.
[ 1 6 ]H .d eJ o n g ,S .E .B e r l o ,P .H o m b r i n ke ta l . ,“ C a r t i l a g e
proteoglycan aggrecan epitopes induce proinﬂammatory
autoreactive T-cell responses in rheumatoid arthritis and
osteoarthritis,” Annals of the Rheumatic Diseases, vol. 69, no.
1, pp. 255–262, 2010.
[17] L. I. Sakkas and C. D. Platsoucas, “The role of T cells in
thepathogenesisofosteoarthritis,”ArthritisandRheumatism,
vol. 56, no. 2, pp. 409–424, 2007.
[18] C. J. Malemud, “Anticytokine therapy for osteoarthritis:
evidence to date,” Drugsand Aging, vol.27,no.2,pp. 95–115,
2010.
[19] M. Kobayashi, G. R. Squires, A. Mousa et al., “Role
of interleukin-1 and tumor necrosis factor α in matrix
degradation of human osteoarthritic cartilage,” Arthritis and
Rheumatism, vol. 52, no. 1, pp. 128–135, 2005.
[20] C. B. Little and A. J. Fosang, “Is cartilage matrix breakdown
an appropriate therapeutic target in osteoarthritis—insights
from studies of aggrecan and collagen proteolysis?” Current
Drug Targets, vol. 11, no. 5, pp. 561–575, 2010.
[21] R. F. Loeser, “Molecular mechanisms of cartilage destruction
in osteoarthritis,” Journal of Musculoskeletal Neuronal Inter-
actions, vol. 8, no. 4, pp. 303–306, 2008.
[22] E. V. Tchetina, G. Squires, and A. R. Poole, “Increased
type II collagen degradation and very early focal cartilage
degeneration is associated with upregulation of chondrocyte
diﬀerentiation related genes in early human articular carti-
lagelesions,”Journal of Rheumatology,vol.32,no.5, pp. 876–
886, 2005.
[ 2 3 ]R .Y a g i ,D .M c B u r n e y ,D .L a v e r t y ,S .W e i n e r ,a n dW .E .H o r -
ton Jr., “Intrajoint comparisons of gene expression patterns
in human osteoarthritis suggest a change in chondrocyte
phenotype,” Journal of Orthopaedic Research,v o l .2 3 ,n o .5 ,
pp. 1128–1138, 2005.
[24] R. Terkeltaub, M. Lotz, K. Johnson et al., “Parathyroid
hormone-related protein is abundant in osteoarthritic car-
tilage, and the parathyroid hormone-related protein 1-
173 isoform is selectively induced by transforming growth
factor β in articular chondrocytes and suppresses generation
of extracellular inorganic pyrophosphate,” Arthritis and
Rheumatism, vol. 41, no. 12, pp. 2152–2164, 1998.
[25] K.vonder Mark,T.Kirsch,A.Nerlich etal.,“Type X collagen
synthesis in human osteoarthritic cartilage: indication of
chondrocyte hypertrophy,” ArthritisandRheumatism,vol.35,
no. 7, pp. 806–811, 1992.
[26] I. Girkontaite, S. Frischholz, P. Lammi et al., “Immunolo-
calization of type X collagen in normal fetal and adultArthritis 9
osteoarthritic cartilage with monoclonal antibodies,” Matrix
Biology, vol. 15, no. 4, pp. 231–238, 1996.
[27] G. D. Walker,M. Fischer, J.Gannon,R. C. Thompson,and T.
R.Oegema,“Expressionoftype-X collageninosteoarthritis,”
Journal of Orthopaedic Research,vol.13,no.1,pp.4–12,1995.
[ 2 8 ]T .K i r s c h ,B .S w o b o d a ,a n dH .D .N a h ,“ A c t i v a t i o no f
annexin II and V expression, terminal diﬀerentiation, min-
eralization and apoptosis in human osteoarthritic cartilage,”
Osteoarthritis and Cartilage, vol. 8, no. 4, pp. 294–302, 2000.
[29] D. Pfander, T. Cramer, E. Schipani, and R. S. Johnson,
“HIF-1α controlsextracellular matrixsynthesisby epiphyseal
chondrocytes,” Journal of Cell Science, vol. 116, no. 9, pp.
1819–1826, 2003.
[30] O. Pullig, G. Weseloh, D. L. Ronneberger, S. M. K¨ ak¨ onen,
and B. Swoboda, “Chondrocyte diﬀerentiation in human
osteoarthritis: expression of osteocalcin in normal and
osteoarthritic cartilage and bone,” Calciﬁed Tissue Interna-
tional, vol. 67, no. 3, pp. 230–240, 2000.
[31] G. A. Karpouzas andR. A. Terkeltaub, “New developmentsin
the pathogenesis of articular cartilage calciﬁcation,” Current
Rheumatology Reports, vol. 1, no. 2, pp. 121–127, 1999.
[32] K. Johnson and R. Terkeltaub, “Upregulated ank expression
in osteoarthritis can promote both chondrocyte MMP-13
expressionandcalciﬁcationviachondrocyte extracellular PPi
excess,” Osteoarthritis and Cartilage, vol. 12, no. 4, pp. 321–
335, 2004.
[33] F. J. Blanco, R. Guitian, E. V´ azquez-Martul, F. J. de Toro,
and F. Galdo, “Osteoarthritis chondrocytes die by apoptosis:
apossiblepathwayforosteoarthritis pathology,”Arthritis and
Rheumatism, vol. 41, no. 2, pp. 284–289, 1998.
[ 3 4 ]C .M .R o b e r t s o n ,A .T .P e n n o c k ,F .L .H a r w o o d ,A .C .
Pomerleau, R. T. Allen, and D. Amiel, “Characterization
of pro-apoptotic and matrix-degradative gene expression
following induction of osteoarthritis in mature and aged
rabbits,” Osteoarthritis and Cartilage, vol. 14, no. 5, pp. 471–
476, 2006.
[35] E. Tchetina, F. Mwale, and A. R. Poole, “Distinct phases of
coordinated early and late gene expression in growth plate
chondrocytes in relationship to cell proliferation, matrix
assembly, remodeling, and cell diﬀerentiation,” Journal of
Bone and Mineral Research, vol. 18, no. 5, pp. 844–851, 2003.
[36] A. V. Ham and D. H. Cormack, Ham’s Histology, Lippincott,
Philadelphia, Pa, USA, 1987.
[37] S. Yamane, E. Cheng, Z. You, and A. H. Reddi, “Gene
expression proﬁling of mouse articular and growth plate
cartilage,” Tissue Engineering, vol. 13, no. 9, pp. 2163–2173,
2007.
[38] P. Krejci, D. Krakow, P. B. Mekikian, and W. R. Wilcox,
“Fibroblast growth factors 1, 2, 17, and 19 are the predom-
inant FGF ligands expressed in human fetal growth plate
cartilage,” Pediatric Research, vol. 61, no. 3, pp. 267–272,
2007.
[ 3 9 ]O .N i l s s o n ,E .A .P a r k e r ,A .H e g d e ,M .C h a u ,K .M .B a r n e s ,
and J. Baron, “Gradients in bone morphogenetic protein-
related gene expression across the growth plate,” Journal of
Endocrinology, vol. 193, no. 1, pp. 75–84, 2007.
[ 4 0 ]H .C .A n d e r s o n ,P .T .H o d g e s ,X .M .A g u i l e r a ,L .M i s s a n a ,
and P. E. Moylan, “Bone morphogenetic protein (BMP)
localization in developing human and rat growth plate,
metaphysis, epiphysis, and articular cartilage,” Journal of
Histochemistry and Cytochemistry, vol. 48, no. 11, pp. 1493–
1502, 2000.
[41] S. Matsunaga, T. Yamamoto, and K. Fukumura, “Temporal
and spatial expressions of transforming growth factor-βs
and their receptors in epiphyseal growth plate,” International
Journal of Oncology, vol. 14, no. 6, pp. 1063–1067, 1999.
[42] T. A. Damron, S. Mathur, J. A. Horton et al., “Temporal
changes in PTHrP, Bcl-2, Bax, caspase, TGF-β,a n dF G F -
2 expression following growth plate irradiation with or
without radioprotectant,” Journal of Histochemistry and
Cytochemistry, vol. 52, no. 2, pp. 157–167, 2004.
[43] M. P. Verdier, S. Seit´ e, K. Guntzer, J. P. Pujol, and K.
Boum´ edi` ene, “Immunohistochemical analysis of transform-
ing growthfactorbeta isoformsandtheirreceptors inhuman
cartilage from normal and osteoarthritic femoral heads,”
Rheumatology International,vol.25,no.2,pp.118–124,2005.
[44] F. Beier, Z. Ali, D. Mok et al., “TGFβ and PTHrP control
chondrocyte proliferation by activating cyclin D1 expres-
sion,” Molecular Biology of the Cell, vol. 12, no. 12, pp. 3852–
3863, 2001.
[45] H. I. Roach, G. Mehta, R. O. C. Oreﬀo, N. M. P. Clarke, and
C. Cooper, “Temporal analysis of rat growth plates: cessation
of growth with age despite presence of a physis,” Journal of
HistochemistryandCytochemistry,vol.51,no.3,pp.373–383,
2003.
[46] F. Mwale, C. Billinghurst, W. Wu et al., “Selective assembly
and remodelling of collagens II and IX associated with
expression of the chondrocyte hypertrophic phenotype,”
Developmental Dynamics, vol. 218, no. 4, pp. 648–662, 2000.
[47] L. A. Neuhold, L. Killar, W. Zhao et al., “Postnatal expres-
sion in hyaline cartilage of constitutively active human
collagenase-3 (MMP-13) induces osteoarthritis in mice,”
Journal of Clinical Investigation, vol. 107, no. 1, pp. 35–44,
2001.
[48] A. L. Armstrong, H. J. Barrach, and M. G. Ehrlich, “Identi-
ﬁcation of the metalloproteinase stromelysin in the physis,”
Journal of Orthopaedic Research, vol. 20, no. 2, pp. 289–294,
2002.
[49] F. H. Wezeman and M. R. Bollnow, “Immunohistochemical
localization of ﬁbroblast growth factor-2 in normal and
brachymorphic mouse tibial growth plate and articular
cartilage,” Histochemical Journal, vol. 29, no. 6, pp. 505–514,
1997.
[50] A. Horner, P. Kemp, C. Summers et al., “Expression and
distribution of transforming growth factor-β isoforms and
their signaling receptors in growing human bone,” Bone,v o l .
23, no. 2, pp. 95–102, 1998.
[ 5 1 ]Y .W a n g ,S .N i s h i d a ,T .S a k a t ae ta l . ,“ I n s u l i n - l i k eg r o w t h
factor-I is essential for embryonic bone development,”
Endocrinology, vol. 147, no. 10, pp. 4753–4761, 2006.
[52] P. de los Rios and D. J. Hill, “Cellular localization and
expression of insulin-like growth factors (IGFS) and IGF
binding proteins within the epiphyseal growth plate of
the ovine fetus: possible functional implications,” Canadian
Journal of Physiology and Pharmacology,v o l .7 7 ,n o .4 ,p p .
235–249, 1999.
[ 5 3 ]D .M .S h i n a r ,N .E n d o ,D .H a l p e r i n ,G .A .R o d a n ,a n d
M. Weinreb, “Diﬀerential expression of insulin-like growth
factor-I (IGF-I) and IGF-II messenger ribonucleic acid in
growing rat bone,” Endocrinology, vol. 132, no. 3, pp. 1158–
1167, 1993.
[54] Q. Ma, X. Li, D. Vale-Cruz, M. L. Brown, F. Beier, and
P. LuValle, “Activating transcription factor 2 controls Bcl-2
promoter activity in growth plate chondrocytes,” Journal of
Cellular Biochemistry, vol. 101, no. 2, pp. 477–487, 2007.
[55] H. Akiyama, M. C. Chaboissier, J. F. Martin, A. Schedl,
and B. de Crombrugghe, “The transcription factor Sox9
has essential roles in successive steps of the chondrocyte10 Arthritis
diﬀerentiationpathwayandisrequired forexpressionofSox5
and Sox6,” Genes and Development, vol.16, no. 21, pp. 2813–
2828, 2002.
[56] D. W. Burton, M. Foster, K. A. Johnson, M. Hiramoto, L.
J. Deftos, and R. Terkeltaub, “Chondrocyte calcium-sensing
receptor expression is up-regulated in early guinea pig knee
osteoarthritis and modulates PTHrP, MMP-13, and TIMP-3
expression,” Osteoarthritis Cartilage, vol. 13, no. 5, pp. 395–
404, 2005.
[57] J. A. Ur´ ı a ,M .B a l b ´ ı n ,J .M .L ´ opez et al., “Collagenase-
3 (MMP-13) expression in chondrosarcoma cells and its
regulation by basic ﬁbroblast growth factor,” American
Journal of Pathology, vol. 153, no. 1, pp. 91–101, 1998.
[ 5 8 ]P .B o r d e n ,D .S o l y m a r ,A .S u c h a r c z u k ,B .L i n d m a n ,P .
Cannon, and R. A. Heller, “Cytokine control of interstitial
collagenase and collagenase-3 gene expression in human
chondrocytes,” J o u r n a lo fB i o l o g i c a lC h e m i s t r y , vol. 271, no.
38, pp. 23577–23581, 1996.
[ 5 9 ]G .H a e u s l e r ,I .W a l t e r ,M .H e l m r e i c h ,a n dM .E g e r b a c h e r ,
“Localization of matrix metalloproteinases, (MMPs) their
tissue inhibitors, and vascular endothelial growth factor
(VEGF) in growth plates of children and adolescents indi-
cates a role for MMPs in human postnatal growth and
skeletal maturation,” Calciﬁed Tissue International, vol. 76,
no. 5, pp. 326–335, 2005.
[ 6 0 ]C .L i ,L .C h e n ,T .I w a t a ,M .K i t a g a w a ,X .Y .F u ,a n dC .X .
Deng, “A Lys644Glu substitution in ﬁbroblast growth factor
receptor 3 (FGFR3) causes dwarﬁsm in mice by activation
of STATs and ink4 cell cycle inhibitors,” Human Molecular
Genetics,vol. 8, no. 1, pp. 35–44, 1999.
[61] K. Tsuchimochi, M. Otero, C. L. Dragomir et al., “GADD45β
enhances Col10a1 transcription via the MTK1/MKK3/6/p38
axisandactivation ofC/EBPβ-TAD4 in terminallydiﬀerenti-
atingchondrocytes,” J o u r n a lo fB i o l o g i c a lC h e m i s t r y ,vol.285,
no. 11, pp. 8395–8407, 2010.
[62] K. Ijiri, L. F. Zerbini, H. Peng et al., “A novel role for
GADD45β as a mediator of MMP-13 gene expression during
chondrocyte terminal diﬀerentiation,” Journal of Biological
Chemistry, vol. 280, no. 46, pp. 38544–38555, 2005.
[ 6 3 ]M .D .K i n k e l ,R .Y a g i ,D .M c B u r n e y ,A .N u g e n t ,a n dW .
E. Horton Jr., “Age-related expression patterns of Bag-
1a n dB c l - 2i ng r o w t hp l a t ea n da r t i c u l a rc h o n d r o c y t e s , ”
Anatomical Record Part A, vol. 279, no. 2, pp. 720–728, 2004.
[64] J. P. Tuckermann, K. Pittois, N. C. Partridge, J. Merregaert,
and P. Angel, “Collagenase-3 (MMP-13) and integral mem-
brane protein 2a (Itm2a) are marker genes of chondro-
genic/osteoblastic cells in bone formation: sequential tem-
poral, and spatial expression of Itm2a, alkaline phosphatase,
MMP-13, and osteocalcin in the mouse,” Journal of Bone and
Mineral Research, vol. 15, no. 7, pp. 1257–1265, 2000.
[65] F. M. D. Henson, M. E. Davies, J. N. Skepper, and L.
B. Jeﬀcott, “Localisation of alkaline phosphatase in equine
growth cartilage,” Journal of Anatomy, vol. 187, no. 1, pp.
151–159, 1995.
[66] R. Pogue and K. Lyons, “BMP signaling in the cartilage
growth plate,” Current Topics in Developmental Biology,v o l .
76, pp. 1–48, 2006.
[67] Y .W ang,F .Middleton,J.A.Horton,L.R eichel,C.E.Farnum,
and T. A. Damron, “Microarray analysis of proliferative and
hypertrophic growth plate zones identiﬁes diﬀerentiation
markers and signal pathways,” Bone, vol. 35, no. 6, pp. 1273–
1293, 2004.
[68] T. Sakou, T. Onishi, T. Yamamoto, T. Nagamine, T. K.
Sampath, and P. Ten Dijke, “Localization of Smads, the
TGF-β family intracellular signaling components during
endochondral ossiﬁcation,” Journal of Bone and Mineral
Research, vol. 14, no. 7, pp. 1145–1152, 1999.
[69] T. Fukunaga, T. Yamashiro, S. Oya, N. Takeshita, M. Taki-
gawa, and T. Takano-Yamamoto, “Connective tissue growth
factor mRNA expression pattern in cartilages is associated
with their type I collagen expression,” Bone, vol. 33, no. 6,
pp. 911–918, 2003.
[70] J. ´ A l v a r e z ,L .C o s t a l e s ,R .S e r r a ,M .B a l b ´ ın, and J. M.
L´ opez, “Expression patterns of matrix metalloproteinases
and vascular endothelial growth factor during epiphyseal
ossiﬁcation,” Journal of Bone and Mineral Research, vol. 20,
no. 6, pp. 1011–1021, 2005.
[71] H. E. MacLean and H. M. Kronenberg, “Localization of
Indian hedgehog and PTH/PTHrP receptor expression in
relation to chondrocyte proliferation during mouse bone
development,” Development Growth and Diﬀerentiation,v o l .
47, no. 2, pp. 59–63, 2005.
[72] J. M. Kindblom, O. Nilsson, T. Hurme, C. Ohlsson, and L.
S¨ avendahl, “Expression and localization of Indian hedgehog
(Ihh) and parathyroid hormone related protein (PTHrP)
in the human growth plate during pubertal development,”
Journal of Endocrinology, vol. 174, no. 2, pp. R1–R6, 2002.
[73] F. Yamashita, K. Sakakida, K. Kusuzaki, H. Takeshita, and
A. Kuzuhara, “Immunohistochemical localization of inter-
leukin 1 in human growth cartilage,” Nippon Seikeigeka
Gakkai Zasshi, vol. 63, no. 5, pp. 562–568, 1989.
[ 7 4 ]P .D u c y ,R .Z h a n g ,V .G e o ﬀroy, A. L. Ridall, and G. Karsenty,
“Osf2/Cbfa1: a transcriptional activator of osteoblast diﬀer-
entiation,” Cell, vol. 89, no. 5, pp. 747–754, 1997.
[75] P. M. van der Kraan, E. N. Blaney Davidson, A. Blom, and
W .B .v a nd e nB e r g ,“ T G F - b e t as i g n a l i n gi nc h o n d r o c y t e
terminal diﬀerentiation and osteoarthritis. Modulation and
integration of signaling pathways through receptor-Smads,”
Osteoarthritis and Cartilage, vol. 17, no. 12, pp. 1539–1545,
2009.
[76] T. Komori,“A fundamentaltranscriptionfactor forbone and
cartilage,” Biochemical and Biophysical Research Communica-
tions, vol. 276, no. 3, pp. 813–816, 2000.
[77] S. Takeda, J. P. Bonnamy, M. J. Owen, P. Ducy, and G.
Karsenty, “Continuous expression of Cbfa1 in nonhyper-
trophic chondrocytes uncovers its ability to induce hyper-
trophic chondrocyte diﬀerentiation and partially rescues
Cbfa1-deﬁcient mice,” Genes and Development, vol. 15, no.
4, pp. 467–481, 2001.
[78] C. Ueta, M. Iwamoto, N. Kanatani et al., “Skeletal malfor-
mations caused by overexpression of Cbfa1 or its dominant
negative form in chondrocytes,” J o u r n a lo fC e l lB i o l o g y ,v o l .
153, no. 1, pp. 87–99, 2001.
[79] D. Porte, J. Tuckermann, M. Becker et al., “Both AP-1 and
Cbfa1-likefactorsarerequired fortheinductionofinterstitial
collagenase by parathyroid hormone,” Oncogene,v o l .1 8 ,n o .
3, pp. 667–678, 1999.
[80] M. J. G. Jim´ enez, M. Balb´ ı n ,J .M .L ´ opez, J. Alvarez, T.
Komori, and C. L´ opez-Ot´ ın, “Collagenase 3 is a target of
Cbfa1, a transcription factor ofthe runt gene family involved
in bone formation,” Molecular and Cellular Biology, vol. 19,
no. 6, pp. 4431–4442, 1999.
[ 8 1 ]F .M w a l e ,E .T c h e t i n a ,C .W .W u ,a n dA .R .P o o l e ,“ T h e
assembly and remodeling of the extracellular matrix in
the growth plate in relationship to mineral deposition and
cellular hypertrophy: an in situ study of collagens II and IX
and proteoglycan,” Journal of Bone and Mineral Research,v o l .
17, no. 2, pp. 275–283, 2002.Arthritis 11
[82] W. Wang, J. Xu, B. Du, and T. Kirsch, “Role of the progressive
ankylosis gene (ank) in cartilage mineralization,” Molecular
and Cellular Biology, vol. 25, no. 1, pp. 312–323, 2005.
[83] W. Wang, J. Xu, and T. Kirsch, “Annexin-mediated Ca
2+
inﬂux regulates growth plate chondrocyte maturation and
apoptosis,”J o u r n a lo fB i o l o gi c a lC h em i s try ,vol.278,no.6,pp.
3762–3769, 2003.
[84] T. Kirsch, “Annexins—their role in cartilage mineralization,”
Frontiers in Bioscience, vol. 10, pp. 576–581, 2005.
[85] W. Wang, J. Xu, and T. Kirsch, “Annexin V and terminal
diﬀerentiation of growth plate chondrocytes,” Experimental
Cell Research, vol. 305, no. 1, pp. 156–165, 2005.
[86] R. K. Gill, R. T. Turner, T. J. Wronski, and N. H. Bell,
“Orchiectomy markedly reduces the concentration of the
three isoforms of transforming growth factor β in rat bone,
and reduction is prevented by testosterone,” Endocrinology,
vol. 139, no. 2, pp. 546–550, 1998.
[87] I. M. Shapiro, C. S. Adams, T. Freeman, and V. Srinivas,
“Fate of the hypertrophic chondrocyte: microenvironmental
perspectives on apoptosis and survival in the epiphyseal
growth plate,” Birth Defects Research Part C, vol. 75, no. 4,
pp. 330–339, 2005.
[88] R. C. Olney, J. Wang, J. E. Sylvester, and E. B. Mougey,
“Growth factor regulation of human growth plate chon-
drocyte proliferation in vitro,” Biochemical and Biophysical
Research Communications, vol. 317, no. 4, pp. 1171–1182,
2004.
[89] M.R.Hutchison,M.H.Bassett,andP.C.White,“Insulin-like
growth factor-I and ﬁbroblast growth factor, but not growth
hormone, aﬀect growth plate chondrocyte proliferation,”
Endocrinology, vol. 148, no. 7, pp. 3122–3130, 2007.
[90] H. M. Kronenberg, “PTHrP and skeletal development,”
Annals of the New York Academy of Sciences, vol. 1068, no. 1,
pp. 1–13, 2006.
[91] T.F. Li,Y. Dong,A.M.Ionescuet al.,“Parathyroid hormone-
related peptide (PTHrP) inhibits Runx2 expression through
the PKA signaling pathway,” Experimental Cell Research,v o l .
299, no. 1, pp. 128–136, 2004.
[ 9 2 ]Y .F .D o n g ,Y .S o u n gd o ,E .M .S c h w a r z ,R .J .O ’ K e e f e ,
and H. Drissi, “Wnt induction of chondrocyte hypertrophy
through the Runx2 transcription factor,” Journal of Cellular
Physiology, vol. 208, no. 1, pp. 77–86, 2006.
[93] D. Kiepe, S. Ciarmatori, A. Haarmann, and B. T¨ onshoﬀ,
“Diﬀerential expression of IGF system components in pro-
liferating vs. diﬀerentiating growth plate chondrocytes: the
functional role of IGFBP-5,” American Journal of Physiology,
vol. 290, no. 2, pp. E363–E371, 2006.
[ 9 4 ] A .C .K a r a p l i s ,A .L u z ,J .G l o w a c k ie ta l . ,“ L e t h a ls k e l e t a ld y s -
plasia from targeted disruption of the parathyroid hormone-
related peptide gene,” Genes and Development,v o l .8 ,n o .3 ,
pp. 277–289, 1994.
[ 9 5 ]N .A m i z u k a ,H .W a r s h a w s k y ,J .E .H e n d e r s o n ,D .G o l t z m a n ,
and A. C. Karaplis, “Parathyroid hormone-related peptide-
depleted mice show abnormal epiphyseal cartilage develop-
ment and altered endochondral bone formation,” Journal of
Cell Biology, vol. 126, no. 6, pp. 1611–1623, 1994.
[ 9 6 ]E .C .W e i r ,W .M .P h i l b r i c k ,M .A m l i n g ,L .A .N e ﬀ,
R. Baron, and A. E. Broadus, “Targeted overexpression
of parathyroid hormone-related peptide in chondrocytes
causes chondrodysplasia and delayed endochondral bone
formation,”Proceedings of the National Academy of Sciencesof
theUnitedStates of America, vol.93,no.19,pp.10240–10245,
1996.
[97] B .Lansk e ,A .C .K arap lis,K .L e ee tal. ,“ PT H / PT H r Pr e c e p t or
in early development and Indian hedgehog-regulated bone
growth,” Science, vol. 273, no. 5275, pp. 663–666, 1996.
[ 9 8 ] A .V o r t k a m p ,K .L e e ,B .L a n s k e ,G .V .S e g r e ,H .M .
Kronenberg, and C. J. Tabin, “Regulation of rate of cartilage
diﬀerentiation by Indian hedgehog and PTH-related pro-
tein,” Science, vol. 273, no. 5275, pp. 613–622, 1996.
[99] E. Yoshida, M. Noshiro, T. Kawamoto, S. Tsutsumi, Y.
Kuruta, and Y. Kato, “Direct inhibition of Indian hedgehog
expression by parathyroid hormone (PTH)/PTH-related
peptide and up-regulation by retinoic acid in growth plate
chondrocyte cultures,” Experimental Cell Research, vol. 265,
no. 1, pp. 64–72, 2001.
[100] B. St-Jacques, M. Hammerschmidt, and A. P. McMahon,
“Indian hedgehog signaling regulates proliferation and
diﬀerentiation of chondrocytes and is essential for bone
formation,” Genes and Development, vol. 13, no. 16, pp.
2072–2086, 1999.
[101] M. Paciﬁci, T. Shimo, C. Gentili et al., “Syndecan-3: a cell-
surface heparansulfate proteoglycanimportant forchondro-
cyte proliferation and function during limb skeletogenesis,”
Journal of Bone and Mineral Metabolism,v o l .2 3 ,n o .3 ,p p .
191–199, 2005.
[102] A. B. Roberts and M. B. Sporn, “Physiological actions and
clinical applications of transforming growth factor-β (TGF-
β),” Growth Factors, vol. 8, no. 1, pp. 1–9, 1993.
[103] G. Gibson, “Active role of chondrocyte apoptosis in endo-
chondral ossiﬁcation,” Microscopy Research and Technique,
vol. 43, no. 2, pp. 191–204, 1998.
[104] X. Yang, L. Chen, X. Xu, C. Li, C. Huang, and C. X. Deng,
“TGF-β/Smad3 signals repress chondrocyte hypertrophic
diﬀerentiation and are required for maintaining articular
cartilage,” J o u r n a lo fC e l lB i o l o g y , vol. 153, no. 1, pp. 35–46,
2001.
[105] R. Serra, A. Karaplis, and P. Sohn, “Parathyroid hormone-
related peptide (PTHrP)-dependent and -independent
eﬀects of transforming growth factor β (TGF-β)on
endochondral bone formation,” J o u r n a lo fC e l lB i o l o g y ,
vol. 145, no. 4, pp. 783–794, 1999.
[106] C. M. Ferguson, E. M. Schwarz, P. R. Reynolds, J. E.
Puzas, R. N. Rosier, and R. J. O’Keefe, “Smad2 and 3
mediate transforming growth factor-β1-induced inhibition
of chondrocyte maturation,” Endocrinology, vol. 141, no. 12,
pp. 4728–4735, 2000.
[107] R. T. Ballock, A. Heydemann, L. M. Wakeﬁeld, K. C.
F l a n d e r s ,A .B .R o b e r t s ,a n dM .B .S p o r n ,“ T G F - β1p r e v e n t s
hypertrophy of epiphyseal chondrocytes: regulation of gene
expression for cartilage matrix proteins and metallopro-
teases,” Developmental Biology, vol. 158, no. 2, pp. 414–429,
1993.
[108] K. Bohme, K. H. Winterhhlter, and P. Bruckner, “Terminal
diﬀerentiation of chondrocytes in culture is a spontaneous
process andis arrested by transforminggrowthfactor-β2a n d
basic ﬁbroblast growth factor in synergy,” Experimental Cell
Research, vol. 216, no. 1, pp. 191–198, 1995.
[109] R. A. Terkeltaub, K. Johnson, D. Rohnow, R. Goomer, D.
Burton, and L. J. Deftos, “Bone morphogenetic proteins and
bFGF exert opposing regulatory eﬀects onPTHrP expression
and inorganic pyrophosphate elaboration in immortalized
murine endochondral hypertrophic chondrocytes (MCT
cells),” Journal of Bone and Mineral Research,v o l .1 3 ,n o .6 ,
pp. 931–941, 1998.12 Arthritis
[110] D. B. Pateder, R. N. Rosier, E. M. Schwarz et al., “PTHrP
expression in chondrocytes, regulation by TGF-β,a n di n t e r -
actions between epiphyseal and growth plate chondrocytes,”
Experimental CellResearch,vol.256,no.2,pp.555–562,2000.
[111] H. Nagai andM. Aoki,“Inhibition of growth plate angiogen-
esis and endochondral ossiﬁcation with diminished expres-
sion of MMP-13 in hypertrophic chondrocytes in FGF-2-
treated rats,”Journal of BoneandMineral Metabolism,v ol.20,
no. 3, pp. 142–147, 2002.
[112] V. Szuts, U. M¨ ollers, K. Bittner et al., “Terminal diﬀerentia-
tionofchondrocytes isarrestedatdistinctstagesidentiﬁedby
their expression repertoire of marker genes,” Matrix Biology,
vol. 17, no. 6, pp. 435–448, 1998.
[113] Q.Wang,X. Wei,T. Zhuet al.,“Bonemorphogenetic protein
2 activates Smad6 gene transcription through bone-speciﬁc
transcription factor Runx2,” J o u r n a lo fB i o l o g i c a lC h e m i s t r y ,
vol. 282, no. 14, pp. 10742–10748, 2007.
[114] T. Kobayashi, K. M. Lyons, A. P. McMahon, and H. M. Kro-
nenberg, “BMP signaling stimulates cellular diﬀerentiation
at multiple steps during cartilage development,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 102, no. 50, pp. 18023–18027, 2005.
[115] B. S. Yoon, R. Pogue, D. A. Ovchinnikov et al., “BMPs
regulate multiple aspects of growth-plate chondrogenesis
through opposing actions on FGF pathways,” Development,
vol. 133, no. 23, pp. 4667–4678, 2006.
[116] M. C. Stewart, R. M. Kadlcek, P. D. Robbins, J. N. Macleod,
and R. T. Ballock, “Expression and activity of the CDK
inhibitor p57Kip2 in chondrocytes undergoing hypertrophic
diﬀerentiation,”JournalofBoneandMineralResearch,vol.19,
no. 1, pp. 123–132, 2004.
[117] D. Zhang, E. M. Schwarz, R. N. Rosier, M. J. Zuscik, J. E.
Puzas, and R. J. O’Keefe, “ALK2 functions as a BMP type
I receptor and induces Indian hedgehog in chondrocytes
during skeletal development,” Journal of Bone and Mineral
Research, vol. 18, no. 9, pp. 1593–1604, 2003.
[118] C. D. Grimsrud, P. R. Romano, M. D’Souza et al., “BMP-
6 is an autocrine stimulator of chondrocyte diﬀerentiation,”
Journal of Bone and Mineral Research, vol. 14, no. 4, pp. 475–
482, 1999.
[119] T. Takahashi, E. A. Morris, and S. B. Trippel, “Bone
morphogenetic protein-2 and -9 regulate the interaction of
insulin-likegrowth factor-I with growth plate chondrocytes,”
International Journal of MolecularMedicine,v ol.20,no .1,p p .
53–57, 2007.
[120] G. Mailhot, M. Yang, A. Mason-Savas, C. A. Mackay,
I. Leav, and P. R. Odgren, “BMP-5 expression increases
during chondrocyte diﬀerentiation in vivo and in vitro and
promotes proliferation and cartilage matrix synthesis in
primarychondrocyte cultures,” Journal ofCellular Physiology,
vol. 214, no. 1, pp. 56–64, 2008.
[121] Z. Laron, “Insulin-like growth factor 1 (IGF-1): a growth
hormone,” Molecular Pathology, vol. 54, no. 5, pp. 311–316,
2001.
[122] W. Hui, A. D. Rowan, and T. Cawston, “Insulin-like growth
factor 1 blocks collagen release and down regulates matrix
metalloproteinase-1, -3, -8, and -13 mRNA expression in
bovine nasal cartilage stimulated with oncostatin M in
combination with interleukin 1α,” Annals of the Rheumatic
Diseases,vol. 60, no. 3, pp. 254–261, 2001.
[123] V. Lefebvre and P. Smits, “Transcriptional control of chon-
drocyte fate and diﬀerentiation,” Birth Defects Research Part
C, vol. 75, no. 3, pp. 200–212,2005.
[124] T. Hattori, C. M¨ uller, S. Gebhard et al., “SOX9 is a major
negative regulator of cartilage vascularization, bone marrow
formationand endochondral ossiﬁcation,”Development,v o l .
137, no. 6, pp. 901–911, 2010.
[125] M. Wuelling and A. Vortkamp, “Transcriptional networks
controlling chondrocyte proliferation and diﬀerentiation
during endochondral ossiﬁcation,” Pediatric Nephrology,v o l .
25, no. 4, pp. 625–631, 2010.
[126] Q. Zhao, H. Eberspaecher, V. Lefebvre, and B. de Crom-
brugghe, “Parallel expression of Sox9 and Col2a1 in cells
undergoing chondrogenesis,” Developmental Dynamics,v o l .
209, no. 4, pp. 377–386, 1997.
[127] B. de Crombrugghe, V. Lefebvre, R. R. Behringer, W. Bi, S.
Murakami, and W. Huang, “Transcriptional mechanisms of
chondrocyte diﬀerentiation,” Matrix Biology, vol. 19, no. 5,
pp. 389–394, 2000.
[128] L. J. Ng, S. Wheatley, G. E. O. Muscat et al., “SOX9
binds DNA, activates transcription, and coexpresses with
type II collagen during chondrogenesis in the mouse,”
Developmental Biology, vol. 183, no. 1, pp. 108–121, 1997.
[129] W. Bi, W. Huang, D. J. Whitworth et al., “Haploinsuﬃciency
of Sox9 results in defective cartilage primordia and pre-
mature skeletal mineralization,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 98,
no. 12, pp. 6698–6703, 2001.
[130] S. Reppe, E. Rian, R. Jemtland, O. K. Olstad, V. T. Gautvik,
and K. M. Gautvik, “Sox-4 messenger RNA is expressed in
theembryonicgrowthplateandregulated viatheparathyroid
hormone/parathyroid hormone-related protein receptor in
osteoblast-like cells,” Journal of Bone and Mineral Research,
vol. 15, no. 12, pp. 2402–2412, 2000.
[131] Y. Soung do, Y. Dong, Y. Wang et al., “Runx3/AML2/Cbfa3
regulates early and late chondrocyte diﬀerentiation,” Journal
of Bone and Mineral Research, vol. 22, no. 8, pp. 1260–1270,
2007.
[132] L. A. Solomon, N. G. B´ erub´ e, and F. Beier, “Transcrip-
tional regulators of chondrocyte hypertrophy,” Birth Defects
Research Part C, vol. 84, no. 2, pp. 123–130, 2008.
[133] H. Drissi, M. Zuscik, R. Rosier, and R. O’Keefe, “Tran-
scriptional regulation of chondrocyte maturation: potential
involvement of transcription factors in OA pathogenesis,”
Molecular Aspects of Medicine, vol. 26, no. 3, pp. 169–179,
2005.
[134] T. F. Li, M. J. Zuscik, A. M. Ionescu et al., “PGE2 inhibits
chondrocyte diﬀerentiation through PKA and PKC signal-
ing,” Experimental Cell Research, vol.300, no.1, pp. 159–169,
2004.
[135] X. Zhang, N. Ziran, J. J. Goater et al., “Primary murine
limb bud mesenchymal cells in long-term culture complete
chondrocyte diﬀerentiation: TGF-β delays hypertrophy and
PGE2 inhibits terminal diﬀerentiation,” Bone, vol. 34, no. 5,
pp. 809–817, 2004.
[136] Z. Schwartz, R. M. Gilley, V. L. Sylvia, D. D. Dean, and B.
D. Boyan, “The eﬀect of prostaglandin E2 on costochondral
chondrocyte diﬀerentiation is mediated by cyclic adenosine
3’,5’-monophosphate and protein kinase C,” Endocrinology,
vol. 139, no. 4, pp. 1825–1834, 1998.
[137] C. Brochhausen, P. Neuland, C. J. Kirkpatrick, R. M.
N¨ using, and G. Klaus, “Cyclooxygenases and prostaglandin
E2 receptors in growth plate chondrocytes in vitro and in
situ—prostaglandin E2 dependent proliferation of growth
plate chondrocytes,” Arthritis Research & Therapy,v o l .8 ,n o .
3, article R78, 2006.Arthritis 13
[138] L. Wei, K. Kanbe, M. Lee et al., “Stimulation of chondrocyte
hypertrophy by chemokine stromal cell-derived factor 1 in
the chondro-osseous junction during endochondral bone
formation,” Developmental Biology, vol. 341, no. 1, pp. 236–
245, 2010.
[139] W. Wang and T. Kirsch, “Annexin V/β5 integrin interactions
regulate apoptosis of growth plate chondrocytes,” Journal of
BiologicalChemistry,vol.281,no.41,pp. 30848–30856,2006.
[140] M. S.Domowicz,M.Cortes, J. G. Henry, and N. B. Schwartz,
“Aggrecan modulation of growth plate morphogenesis,”
Developmental Biology, vol. 329, no. 2, pp. 242–257, 2009.
[141] L.vanderWeyden,L.Wei,J.Luo etal.,“Functionalknockout
of the matrilin-3 gene causes premature chondrocyte mat-
uration to hypertrophy and increases bone mineral density
and osteoarthritis,” American Journal of Pathology, vol. 169,
no. 2, pp. 515–527, 2006.
[142] O. Barbieri, S. Astigiano, M. Morini et al., “Depletion of
cartilagecollagenﬁbrilsinmicecarryingadominantnegative
Col2a1 transgene aﬀects chondrocyte diﬀerentiation,” Amer-
ican Journal of Physiology, vol. 285, no. 6, pp. C1504–C1512,
2003.
[143] R. M. Borzi., E. Olivotto, S. Pagani et al., “Matrix metal-
loproteinase 13 loss associated with impaired extracellular
matrix remodeling disrupts chondrocyte diﬀerentiation by
concerted eﬀects on multiple regulatory factors,” Arthritis
and Rheumatism, vol. 62, no. 8, pp. 2370–2381, 2010.
[144] C. J. Malemud, “Matrix metalloproteinases: role in skeletal
development and growth plate disorders,” Frontiers in Bio-
science, vol. 11, no. 2, pp. 1702–1715, 2006.
[145] Q. Chen, D. M. Johnson, D. R. Haudenschild, and P. F.
Goetinck, “Progression and recapitulation of the chondro-
cyte diﬀerentiation program: cartilage matrix protein is a
markerforcartilagematuration,”Developmental Biology,v ol.
172, no. 1, pp. 293–306, 1995.
[146] J. A. Buckwalter and H. J. Mankin, “Articular cartilage repair
and transplantation,” Arthritis and Rheumatism, vol. 41, no.
8, pp. 1331–1342, 1998.
[147] T.E.Hardingham,A.J.Fosang,andJ.Dudhia,“Aggrecan,the
chondroitin sulfate/keratan sulfate proteoglycan from carti-
lage,” in Articular Cartilage and Osteoarthritis, K. Kuettner et
al., Ed., Raven Press, New York, NY, USA, 1992.
[148] T. Aigner, A. Zien, D. Hanisch, and R. Zimmer, “Gene
expressioninchondrocytes assessedwithuseofmicroarrays,”
Journal of Boneand Joint Surgery. American,v ol.85,no .1,p p .
117–123, 2003.
[149] L. C. Tetlow, D. J. Adlam, and D. E. Woolley, “Matrix met-
alloproteinase and proinﬂammatory cytokine production by
chondrocytes of human osteoarthritic cartilage: associations
with degenerative changes,” Arthritis and Rheumatism,v o l .
44, no. 3, pp. 585–594, 2001.
[150] W. B. van den Berg, “Growth factors in experimental
osteoarthritis: transforming growth factor β pathogenic?”
Journal of Rheumatology, vol. 22, no. 43, pp. 143–145, 1995.
[151] X. Chen, C. M. Macica, A. Nasiri, and A. E. Broadus,
“Regulation of articular chondrocyte proliferation and dif-
ferentiation by Indian hedgehog and parathyroid hormone-
related protein in mice,” Arthritis and Rheumatism, vol. 58,
no. 12, pp. 3788–3797, 2008.
[152] Y. Hiraki, H. Inoue, K. I. Iyama et al., “Identiﬁcation
of chondromodulin I as a novel endothelial cell growth
inhibitor: puriﬁcation and its localization in the avascular
zone of epiphyseal cartilage,” J o u r n a lo fB i o l o g i c a lC h e m i s t r y ,
vol. 272, no. 51, pp. 32419–32426, 1997.
[153] H. Kitahara, T. Hayami, K. Tokunaga et al., “Chondro-
modulin-I expression in rat articular cartilage,” Archives of
Histology and Cytology, vol. 66, no. 3, pp. 221–228, 2003.
[154] K.Ijiri,L.F.Zerbini,H.Pengetal.,“Diﬀerential expressionof
GADD45β in normal and osteoarthritic cartilage: potential
role in homeostasis of articular chondrocytes,” Arthritis and
Rheumatism, vol. 58, no. 7, pp. 2075–2087, 2008.
[155] H. W. Zhou, S. Q. Lou, and K. Zhang, “Recovery of function
inosteoarthriticchondrocytes inducedbyp16INK4a-speciﬁc
siRNA in vitro,” Rheumatology, vol. 43, pp. 555–568, 2004.
[156] T. Aigner andL.McKenna,“Molecular pathologyandpatho-
biology of osteoarthritic cartilage,” Cellular and Molecular
Life Sciences, vol. 59, no. 1, pp. 5–18, 2002.
[157] A. R. Poole, “What type of cartilage repair are we attempting
to attain?” Journal of Bone and Joint Surgery. American,v o l .
85, no. 1, pp. 40–44, 2003.
[158] A. Scharstuhl, H. L. Glansbeek, H. M. van Beuningen,
E. L. Vitters, P. M. van der Kraan, and W. B. van den
Berg, “Inhibitionof endogenous TGF-β during experimental
osteoarthritis prevents osteophyte formation and impairs
cartilage repair,” Journal of Immunology, vol. 169, no. 1, pp.
507–514, 2002.
[159] P. K. Bos, G. J. V. M. van Osch, D. A. Frenz, J. A.
N. Verhaar, and H. L. Verwoerd-Verhoef, “Growth factor
expression in cartilage wound healing: temporal and spatial
immunolocalization in a rabbit auricular cartilage wound
model,” Osteoarthritis and Cartilage, vol. 9, no. 4, pp. 382–
389, 2001.
[160] A. H. White, R. E. B. Watson, B. Newman, A. J. Freemont,
and G. A. Wallis, “Annexin VIII is diﬀerentially expressed
by chondrocytes in the mammalian growth plate during
endochondral ossiﬁcation and in osteoarthritic cartilage,”
Journal of Bone and Mineral Research, vol. 17, no. 10, pp.
1851–1858, 2002.
[161] G. E. Kempson, H. Muir, C. Pollard, and M. Tuke, “The
tensile properties of the cartilage of human femoral condyles
related to the content of collagen and glycosaminoglycans,”
Biochimica et Biophysica Acta, vol. 297, no. 2, pp. 456–472,
1973.
[162] A. R. Poole, L. C. Rosenberg, A. Reiner, M. Ionescu,
E. Bogoch, and P. J. Roughley, “Contents and distribu-
tions of the proteoglycans decorin and biglycan in normal
and osteoarthritic human articular cartilage,” Journal of
Orthopaedic Research, vol. 14, no. 5, pp. 681–689, 1996.
[163] D. Pfander, B. Swoboda, and T. Kirsch, “Expression of early
and late diﬀerentiation markers (proliferating cell nuclear
antigen, syndecan-3, annexin VI, and alkaline phosphatase)
by human osteoarthritic chondrocytes,” American Journal of
Pathology, vol. 159, no. 5, pp. 1777–1783, 2001.
[164] W. Wu, R. C. Billinghurst, I. Pidoux et al., “Sites of
collagenase cleavage and denaturation of type II collagen
in aging and osteoarthritic articular cartilage and their
relationshiptothedistribution ofmatrixmetalloproteinase1
and matrix metalloproteinase 13,” Arthritis and Rheumatism,
vol. 46, no. 8, pp. 2087–2094, 2002.
[165] J.Quintavalla,C. Kumar,S.Daouti,E. Slosberg, andS.Uziel-
Fusi, “Chondrocyte cluster formationin agarosecultures asa
functionalassayto identifygenes expressed inosteoarthritis,”
Journal of Cellular Physiology, vol. 204, no. 2, pp. 560–566,
2005.
[166] A. Maroudas, M. T. Bayliss, and M. F. Venn, “Further studies
onthecompositionofhumanfemoralheadcartilage,”Annals
of the Rheumatic Diseases, vol. 39, no. 5, pp. 514–523, 1980.14 Arthritis
[167] S. A. Semevolos, M. L. Strassheim, J. L. Haupt, and A. J.
Nixon, “Expression patterns of hedgehog signaling peptides
in naturally acquired equine osteochondrosis,” Journal of
Orthopaedic Research, vol. 23, no. 5, pp. 1152–1159, 2005.
[168] T. Aigner, M. Hemmel, D. Neureiter et al., “Apoptotic
cell death is not a widespread phenomenon in normal
aging and osteoarthritic human articular knee cartilage: a
study of proliferation, programmed cell death (apoptosis),
and viability of chondrocytes in normal and osteoarthritic
humankneecartilage,”Arthritis andRheumatism,vol.44,no.
6, pp. 1304–1312, 2001.
[169] K. K¨ u h n ,D .D .D ’ L i m a ,S .H a s h i m o t o ,a n dM .L o t z ,“ C e l l
death incartilage,” Osteoarthritis and Cartilage,v o l .1 2 ,n o .1 ,
pp. 1–16, 2004.
[170] H. Dumond, N. Presle, P. Pottie et al., “Site speciﬁc changes
in gene expression and cartilage metabolism during early
experimental osteoarthritis,” Osteoarthritis and Cartilage,
vol. 12, no. 4, pp. 284–295, 2004.
[171] J. C. Fernandes, J. Martel-Pelletier, V. Lascau-Coman et
al., “Collagenase-1 and collagenase-3 synthesis in normal
and early experimental osteoarthritic canine cartilage: an
immunohistochemical study,” Journal of Rheumatology,v o l .
25, no. 8, pp. 1585–1594, 1998.
[172] E. V. Tchetina, M. Kobayashi, T. Yasuda, T. Meijers, I.
Pidoux, and A. R. Poole, “Chondrocyte hypertrophy can be
induced by a cryptic sequence of type II collagen and is
accompanied by the induction of MMP-13 and collagenase
activity: implications for development and arthritis,” Matrix
Biology, vol. 26, no. 4, pp. 247–258, 2007.
[173] H. Lorenz, W. Wenz, M. Ivancic, E. Steck, and W. Richter,
“Early and stable upregulation of collagen type II, collagen
type I and YKL40 expression levels in cartilage during
early experimental osteoarthritis occurs independent of joint
location and histological grading,” Arthritis Research &
Therapy, vol. 7, no. 1, pp. R156–R165, 2005.
[174] J. R. Matyas, P. F. Ehlers, D. Huang, and M. E. Adams, “The
early molecular natural history of experimental osteoarthri-
tis: I. Progressive discoordinate expression of aggrecan and
type II procollagen messengerrna in thearticular cartilage of
adult animals,” Arthritis and Rheumatism,v o l .4 2 ,n o .5 ,p p .
993–1002, 1999.
[175] J. R. Matyas, D. Huang, M. Chung, and M. E. Adams,
“Regional quantiﬁcation of cartilage type II collagen and
aggrecan messenger RNA in joints with early experimental
osteoarthritis,” Arthritis and Rheumatism,v o l .4 6 ,n o .6 ,p p .
1536–1543, 2002.
[176] C. T. G. Appleton, D. D. McErlain, V. Pitelka et al., “Forced
mobilization accelerates pathogenesis: characterization of
a preclinical surgical model of osteoarthritis,” Arthritis
Research & Therapy, vol. 9, article R13, 2007.
[177] F. Moldovan, J. Pelletier, F. C. Jolicoeur, J. M. Cloutier, and
J. Martel-Pelletier, “Diacerhein and rhein reduce the ICE-
induced IL-1β and IL-18 activation in human osteoarthritic
cartilage,” Osteoarthritis and Cartilage, vol. 8, no. 3, pp. 186–
196, 2000.
[178] B. Rolauﬀs, J. M. Williams, M. Aurich, A. J. Grodzinsky,
K. E. Kuettner, and A. A. Cole, “Proliferative remodeling of
the spatial organization of human superﬁcial chondrocytes
distantfromfocalearlyosteoarthritis,”Arthritis and Rheuma-
tism, vol. 62, no. 2, pp. 489–498, 2010.
[179] N. Miosge, M. Hartmann, C. Maelicke, and R. Herken,
“Expression of collagen type I and type II in consecutive
stages of human osteoarthritis,” Histochemistry and Cell
Biology, vol. 122, no. 3, pp. 229–236, 2004.
[180] A.P.Hollander,I.Pidoux,A.Reiner, C.Rorabeck,R.Bourne,
and A. R. Poole, “Damage to type II collagen in aging and
osteoarthritisstartsatthearticularsurface,originatesaround
chondrocytes, andextends into the cartilage with progressive
degeneration,” Journal of Clinical Investigation,v o l .9 6 ,n o .6 ,
pp. 2859–2869, 1995.
[181] A. R. Poole, M. Alini, and A. P. Hollander, “Cellular biology
of cartilage degradation,” in Mechanisms and Models in
Rheumatoid Arthritis, pp. 163–203, Academic Press, London,
UK, 1995.
[182] T. Aigner, A. Zien, A. Gehrsitz, P. M. Gebhard, and L.
McKenna, “Anabolic and catabolic gene expression pattern
analysis in normal versus osteoarthritic cartilage using com-
plementary DNA-array technology,” Arthritis and Rheuma-
tism, vol. 44, no. 12, pp. 2777–2789, 2001.
[183] M. Gebauer, J. Saas, J. Haag et al., “Repression of anti-
proliferative factor Tob1 in osteoarthritic cartilage,” Arthritis
Research & Therapy, vol. 7, no. 2, pp. R274–R284, 2005.
[184] A. C. Bay-Jensen, T. L. Andersen, N. Charni-Ben Tabassi
et al., “Biochemical markers of type II collagen breakdown
and synthesis are positioned at speciﬁc sites in human
osteoarthritic knee cartilage,” Osteoarthritis and Cartilage,
vol. 16, no. 5, pp. 615–623, 2008.
[185] D. Pfander, R. Rahmanzadeh, and E. E. Scheller, “Presence
and distribution of collagen II, collagen I, ﬁbronectin,
and tenascin in rabbit normal and osteoarthritic cartilage,”
Journal of Rheumatology, vol. 26, no. 2, pp. 386–394, 1999.
[186] K. Veje, J. L. Hyllested-Winge, and K. Ostergaard, “Topo-
graphicandzonaldistributionoftenascininhumanarticular
cartilage from femoral heads: normal versus mild and severe
osteoarthritis,” Osteoarthritis and Cartilage,v ol.11,no .3,p p .
217–227, 2003.
[187] H. Lorenz and W. Richter, “Osteoarthritis: cellular and
molecular changes in degenerating cartilage,” Progress in
HistochemistryandCytochemistry,vol.40,no.3,pp.135–163,
2006.
[188] E. N. Blaney Davidson, E. L. Vitters, P. M. van der Kraan,
and W.B. van den Berg, “Expression of transforminggrowth
factor-β (TGFβ)a n dt h eT G F β signalling molecule SMAD-
2P in spontaneous and instability-induced osteoarthritis:
role in cartilage degradation, chondrogenesis and osteophyte
formation,” Annals of the Rheumatic Diseases, vol. 65, no. 11,
pp. 1414–1421, 2006.
[189] N. Yatsugi, T. Tsukazaki,M. Osaki,T. Koji, S. Yamashita,and
H. Shindo, “Apoptosis of articular chondrocytes in rheuma-
toidarthritis andosteoarthritis:correlationofapoptosiswith
degree of cartilage destruction and expression of apoptosis-
related proteins of p53 and c-myc,” Journal of Orthopaedic
Science, vol. 5, no. 2, pp. 150–156, 2000.
[190] P. Garnero, X. Ayral, J. C. Rousseau et al., “Uncoupling of
type II collagen synthesis and degradation predicts progres-
sion of joint damage in patients with knee osteoarthritis,”
Arthritis and Rheumatism, vol. 46, no. 10, pp. 2613–2624,
2002.
[191] E. G´ omez-Barrena, O. S´ anchez-Pernaute, R. Largo, E. Calvo,
P. Esbrit, and G. Herrero-Beaumont, “Sequential changes of
parathyroid hormone related protein (PTHrP) in articular
cartilage during progression of inﬂammatory and degener-
ative arthritis,” Annals of the Rheumatic Diseases, vol. 63, no.
8, pp. 917–922, 2004.
[192] M. Pombo-Suarez, M. T. Casta˜ no-Oreja, M. Calaza, J.
Gomez-Reino,andA.Gonzalez,“Diﬀerentialupregulationof
thethreetransforminggrowthfactorbeta isoformsinhumanArthritis 15
osteoarthritic cartilage,” Annals of the Rheumatic Diseases,
vol. 68, no. 4, pp. 568–571, 2009.
[193] C. J. Brew, P. D. Clegg, R. P. Boot-Handford, J. G. Andrew,
and T. Hardingham, “Gene expression in human chondro-
cytes in late osteoarthritis is changed in both ﬁbrillated and
intact cartilage without evidence of generalised chondrocyte
hypertrophy,” Annals of the Rheumatic Diseases,v ol.69,no .1,
pp. 234–240, 2010.
[194] T. Hayami, M. Pickarski, Y. Zhuo, G. A. Wesolowski, G.
A. Rodan, and LE. T. Duong, “Characterization of articular
cartilage and subchondral bone changes in the rat anterior
cruciate ligament transection and meniscectomized models
of osteoarthritis,” Bone, vol. 38, no. 2, pp. 234–243, 2006.
[195] T. Pufe, W. Petersen, B. Tillmann, and R. Mentlein, “The
splice variants VEGF121 and VEGF189 of the angiogenic
peptide vascular endothelial growth factor are expressed in
osteoarthritic cartilage,” Arthritis and Rheumatism, vol. 44,
no. 5, pp. 1082–1088, 2001.
[196] M. Sharif, J. Kirwan, N. Charni, L. J. Sandell, C. Whittles,
and P. Garnero, “A 5-yr longitudinal study of type IIA
collagen synthesis and total type II collagen degradation in
patients with knee osteoarthritis—association with disease
progression,”Rheumatology,vol.46,no.6,pp.938–943,2007.
[197] E. V. Tchetina, J. Antoniou, M. Tanzer, D. J. Zukor, and
A. R. Poole, “Transforming growth factor-β2 suppresses
collagen cleavage in cultured human osteoarthritic cartilage,
reduces expression of genes associated with chondrocyte
hypertrophy anddegradation,andincreasesprostaglandinE2
production,” American Journal of Pathology, vol. 168, no. 1,
pp. 131–140, 2006.
[198] W.Hui, T.Cawston,andA.D.Rowan,“Transforminggrowth
factor β1 and insulin-like growth factor 1 block collagen
degradation induced by oncostatin M in combination with
tumour necrosis factor α from bovine cartilage,” Annals of
the Rheumatic Diseases,vol. 62, no. 2, pp. 172–174, 2003.
[199] J. Jiang, N. L. Leong, J. C. Mung, C. Hidaka, and H.
H. Lu, “Interaction between zonal populations of articular
chondrocytes suppresses chondrocyte mineralization and
this process is mediated by PTHrP,” Osteoarthritis and
Cartilage, vol. 16, no. 1, pp. 70–82, 2008.
[200] W. Kaﬁenah, S. Mistry, S. C. Dickinson, T. J. Sims, I. Lear-
month, and A. P. Hollander, “Three-dimensional cartilage
tissue engineering using adult stem cells from osteoarthritis
patients,” Arthritis and Rheumatism, vol. 56, no. 1, pp. 177–
187, 2007.
[201] E. V. Tchetina, J. A. Di Battista, D. J. Zukor, J. Antoniou,
and A. R. Poole, “Prostaglandin PGE2 at very low con-
centrations suppresses collagen cleavage in cultured human
osteoarthritic articular cartilage: this involves a decrease
in expression of proinﬂammatory genes, collagenases and
COL10A1, a gene linked to chondrocyte hypertrophy,”
Arthritis Research & Therapy, vol. 9, no. 4, p. R75, 2007.
[202] J.Akaogi,T.Nozaki,M.Satoh,andH.Yamada,“RoleofPGE2
and EP receptors in the pathogenesis of rheumatoid arthritis
and as a novel therapeutic strategy,” Endocrine, Metabolic &
Immune Disorders-Drug Targets, vol. 6, no. 4, pp. 383–394,
2006.
[203] M. Attur, H. E. Al-Mussawir,J. Patel et al., “Prostaglandin E2
exerts cataboliceﬀects inosteoarthritis cartilage:evidence for
signaling via the EP4 receptor,” Journal of Immunology,v o l .
181, no. 7, pp. 5082–5088, 2008.
[204] D. D’Lima, J. Hermida, S. Hashimoto, C. Colwell, and M.
Lotz, “Caspase inhibitors reduce severity of cartilage lesions
in experimental osteoarthritis,” Arthritis and Rheumatism,
vol. 54, no. 6, pp. 1814–1821, 2006.
[205] A. Scharstuhl, E. L. Vitters, P. M. van der Kraan, and
W. B. van den Berg, “Reduction of osteophyte formation
and synovial thickening by adenoviral overexpression of
transforming growth factor β/bone morphogenetic protein
inhibitors during experimental osteoarthritis,” Arthritis and
Rheumatism, vol. 48, no. 12, pp. 3442–3451, 2003.
[206] A. C. Lin, B. L. Seeto, J. M. Bartoszko et al., “Modulating
hedgehog signaling can attenuate the severity of osteoarthri-
tis,” Nature Medicine, vol. 15, no. 12, pp. 1421–1425, 2009.
[207] E. Araldi and E. Schipani, “MicroRNA-140 and the silencing
of osteoarthritis,” Genesand Development, vol.24,no. 11,pp.
1075–1080, 2010.
[208] S.S.Glasson,R. Askew,B.Sheppard et al.,“Deletion ofactive
ADAMTS5prevents cartilagedegradationinamurinemodel
of osteoarthritis,” Nature, vol. 434, no. 7033, pp. 644–648,
2005.
[209] S. Kamekura, Y. Kawasaki, K. Hoshi et al., “Contribution
of runt-related transcription factor 2 to the pathogenesis
of osteoarthritis in mice after induction of knee joint
instability,” Arthritis and Rheumatism,v o l .5 4 ,n o .8 ,p p .
2462–2470, 2006.
[210] A. R. Klatt, G. Klinger, O. Neum¨ uller et al., “TAK1 downreg-
ulation reduces IL-1β induced expression ofMMP13,MMP1
and TNF-alpha,” Biomedicine and Pharmacotherapy, vol. 60,
no. 2, pp. 55–61, 2006.
[211] J. Weisser, B. Rahfoth, A. Timmermann, T. Aigner, R.
Br¨ auer, and K. von der Mark, “Role of growth factors in
rabbit articular cartilage repair by chondrocytes in agarose,”
Osteoarthritis and Cartilage, vol. 9, pp. S48–S54, 2001.
[212] T.Yamamoto,S.Wakitani,K.Imotoetal.,“Fibroblastgrowth
factor-2 promotes the repair of partial thickness defects of
articular cartilage in immature rabbits but not in mature
rabbits,” Osteoarthritis and Cartilage, vol. 12, no. 8, pp. 636–
641, 2004.
[213] P. R. Elford, M. Graeber, H. Ohtsu et al., “Induction of
swelling, synovialhyperplasia and cartilage proteoglycan loss
upon intra-articular injection of transforming growth factor
β-2 in the rabbit,” Cytokine,vol. 4, no. 3, pp. 232–238, 1992.
[214] S. B. Trippel, “Growth factor inhibition: potential role in the
etiopathogenesis of osteoarthritis,” Clinical Orthopaedics and
Related Research, no. 427, pp. S47–S52, 2004.
[215] J. I. Shida, S. Jingushi, T. Izumi, T. Ikenoue, and Y.
Iwamoto,“Basicﬁbroblastgrowthfactorregulates expression
of growth factors in rat epiphyseal chondrocytes,” Journal of
Orthopaedic Research, vol. 19, no. 2, pp. 259–264, 2001.
[216] P.C.Yaeger,T.L.Masi,J.L.BuckdeOrtiz,F.Binette,R.Tubo,
and J. M. McPherson, “Synergistic action of transforming
growth factor-β and insulin-like growth factor-I induces
expression of type II collagen and aggrecan genes in adult
human articular chondrocytes,” Experimental Cell Research,
vol. 237, no. 2, pp. 318–325, 1997.
[217] A. Barbero, S. Grogan, D. Sch¨ afer, M. Heberer, P. Mainil-
Varlet,andI.Martin,“Agerelated changesinhumanarticular
chondrocyte yield, proliferation and post-expansion chon-
drogenic capacity,” Osteoarthritis and Cartilage, vol. 12, no.
6, pp. 476–484, 2004.
[218] A. V. Babarina, U. M¨ o l l e r s ,K .B i t t n e r ,P .V i s c h e r ,a n dP .
Bruckner, “Role of the subchondral vascular system in endo-
chondral ossiﬁcation: endothelial cell-derived proteinases
derepress late cartilage diﬀerentiation in vitro,” Matrix
Biology, vol. 20, no. 3, pp. 205–213, 2001.16 Arthritis
[219] J. O. P. Cheung, M. C. Hillarby, S. Ayad et al., “A novel
cell culture model of chondrocyte diﬀerentiation during
mammalian endochondral ossiﬁcation,” Journal of Bone and
Mineral Research, vol. 16, no. 2, pp. 309–318, 2001.
[220] M. J. Zuscik, J. F. Baden, Q. Wu et al., “5-azacytidine
alters TGF-β and BMP signaling and induces maturation in
articular chondrocytes,” Journal of Cellular Biochemistry,v o l .
92, no. 2, pp. 316–331, 2004.
[221] M. L. Ho, JE. K. Chang, S. C. Wu et al., “A novel terminal
diﬀerentiation model of human articular chondrocytes in
three-dimensional cultures mimickingchondrocytic changes
inosteoarthritis,”CellBiologyInternational,v ol.30,no .3,p p .
288–294, 2006.
[222] T. Yasuda, E. Tchetina, K. Ohsawa et al., “Peptides of type
II collagen can induce the cleavage of type II collagen and
aggrecan in articular cartilage,” Matrix Biology,v o l .2 5 ,n o .7 ,
pp. 419–429, 2006.
[223] T. Yasuda and A. R. Poole, “A ﬁbronectin fragment induces
type II collagen degradation by collagenase through an
interleukin-1-mediated pathway,” Arthritis and Rheumatism,
vol. 46, no. 1, pp. 138–148, 2002.
[224] G. A. Homandberg, “Cartilage damage by matrix degrada-
tion products: ﬁbronectin fragments,” Clinical Orthopaedics
and Related Research, no. 391, pp. S100–S107, 2001.
[225] R. Serra, M. Johnson, E. H. Filvaroﬀ et al., “Expression of a
truncated, kinase-defective TGF-β type II receptor in mouse
skeletaltissuepromotes terminalchondrocyte diﬀerentiation
and osteoarthritis,” J o u r n a lo fC e l lB i o l o gy , vol.139,no. 2, pp.
541–552, 1997.
[226] T. F. Li, M. Darowish, M. J. Zuscik et al., “Smad3-deﬁcient
chondrocytes have enhanced BMP signaling and accelerated
diﬀerentiation,”JournalofBoneandMineralResearch,vol.21,
no. 1, pp. 4–16, 2006.
[227] G. Valverde-Franco, J. S. Binette, . et al., “Defects in articular
cartilage metabolism and early arthritis in ﬁbroblast growth
factor receptor 3 deﬁcient mice,” Human Molecular Genetics,
vol. 15, no. 11, pp. 1783–1792, 2006.
[228] C. T. G. Appleton, S. E. Usmani, S. M. Bernier, T. Aigner,
and F. Beier, “Transforming growth factor α suppression of
articular chondrocyte phenotype and Sox9 expression in a
rat model of osteoarthritis,” Arthritis and Rheumatism,v o l .
56, no. 11, pp. 3693–3705, 2007.
[229] M. B. Goldring and K. B. Marcu, “Cartilage homeostasis in
healthand rheumatic diseases,”Arthritis Research & Therapy,
vol. 11, no. 3, article 224, 2009.
[230] D. L. Cecil, K. Johnson, J. Rediske, M. Lotz, A. M. Schmidt,
and R. Terkeltaub, “Inﬂammation-induced chondrocyte
hypertrophy is driven by receptor for advanced glycation end
products,” Journal of Immunology, vol. 175, no. 12, pp. 8296–
8302, 2005.
[231] D. Merz, R. Liu, K. Johnson,and R. Terkeltaub, “IL-8/CXCl8
and growth-related oncogene α/CXCL1 induce chondrocyte
hypertrophic diﬀerentiation,” Journal of Immunology,v o l .
171, no. 8, pp. 4406–4415, 2003.
[232] C. Baug´ e, F. Legendre, S. Leclercq et al., “Interleukin-1β
impairment of transforming growth factor β1 signaling by
down-regulation of transforming growth factor β receptor
type II and up-regulation of Smad7 in human articular
chondrocytes,” Arthritis and Rheumatism,v o l .5 6 ,n o .9 ,p p .
3020–3032, 2007.